

**LOCALIZATION AND REGULATION  
OF PEROXIREDOXINS IN HUMAN  
LUNG AND LUNG DISEASES**

**SIRI  
LEHTONEN**

Faculty of Medicine,  
Department of Internal Medicine,  
Clinical Research Center,  
University of Oulu;  
Oulu University Hospital;  
Division of Pulmonary Diseases,  
University of Helsinki

OULU 2005





*SIRI LEHTONEN*

**LOCALIZATION AND REGULATION  
OF PEROXIREDOXINS IN HUMAN  
LUNG AND LUNG DISEASES**

Academic Dissertation to be presented with the assent of  
the Faculty of Medicine, University of Oulu, for public  
discussion in the Auditorium 7 of Oulu University  
Hospital, on June 22nd, 2005, at 12 noon

OULUN YLIOPISTO, OULU 2005

Copyright © 2005  
University of Oulu, 2005

Supervised by  
Professor Vuokko Kinnula

Reviewed by  
Docent Sisko Anttila  
Doctor Anna-Liisa Levonen

ISBN 951-42-7764-3 (nid.)  
ISBN 951-42-7765-1 (PDF) <http://herkules.oulu.fi/isbn9514277651/>  
ISSN 0355-3221 <http://herkules.oulu.fi/issn03553221/>

OULU UNIVERSITY PRESS  
OULU 2005

## **Lehtonen, Siri, Localization and regulation of peroxiredoxins in human lung and lung diseases**

Faculty of Medicine, Department of Internal Medicine, Clinical Research Center, University of Oulu, P.O.Box 5000, FIN-90014 University of Oulu, Finland; Oulu University Hospital, P.O.Box 10, FIN-90029 OYS, Finland; Division of Pulmonary Diseases, University of Helsinki, P.O.Box 22, FIN-00014 University of Helsinki, Finland  
2005  
Oulu, Finland

### ***Abstract***

Reactive oxygen species (ROS) can cause severe damage to cells and organs but they are also important mediators of inflammatory responses and cellular signalling. Due to the significant role of ROS, the cells have evolved a broad antioxidative system to regulate the concentration of these species. Peroxiredoxins (Prxs) are enzymes that participate in the regulation of the cellular redox-homeostasis by detoxifying hydrogen peroxide. Prxs are not classified as conventional antioxidant enzymes and their physiological role, whether protective or regulatory, is still unclear.

The aim of this project was to study the localization and regulation of Prxs in normal human lung and also their role in selected lung disorders (pulmonary sarcoidosis, pleural mesothelioma, lung carcinomas and chronic obstructive disorder, COPD). Additionally the expression of thioredoxin (Trx) and thioredoxin reductase (TrxR) was analysed in the lung of smokers and COPD patients. These enzymes are important reductants in cell and Prxs are one of their targets. Lung is an important organ in the field of ROS and antioxidant research since it is especially vulnerable to exogenous oxidative stress caused by pollutants, cigarette smoke and also by high oxygen pressure.

The results showed that all six human Prxs were expressed in healthy human lung but in a cell-specific manner. The most prominent expression was detected in the epithelium and in macrophages, the cells most prone to oxidative stress. There were also differences in subcellular locations of Prxs.

The expression of Prxs in non-malignant lung diseases (pulmonary sarcoidosis and COPD) and in smoker's lung was very similar with that in normal lung. Higher expression of Prx V and VI was detected in a subpopulation of macrophages sampled from COPD patients' lung. In contrast, Trx expression was induced in the bronchial epithelium of smoker's lung.

Differences in the expression compared to normal lung were seen in lung malignancies (pleural mesothelioma and lung carcinomas). Interestingly, different Prxs were highly expressed in different types of carcinomas. In pleural mesothelioma, all Prxs except Prx IV were highly expressed when compared to normal pleura, in adenocarcinoma Prxs I, II, VI and especially IV, and in squamous cell carcinoma Prxs I, II and IV were upregulated.

Tests performed on cultured cells *in vitro* revealed only a minor increase in the Prx expression after severe oxidant stress in malignant lung cell line originating from alveolar type II pneumocytes (A549) or non-malignant cell line derived from bronchial epithelium. None of the tested growth factors or cytokines affected Prx expression or oxidation state, but severe oxidant stress influenced remarkably the oxidation state of the Prxs.

**Keywords:** antioxidant enzyme, chronic obstructive pulmonary disease, lung neoplasms, mesothelioma, oxidants, peroxiredoxin, sarcoidosis



## Acknowledgements

This work was carried out in the Department of Internal Medicine and the Clinical research Center of the University of Oulu and Oulu University Hospital during the years 2000-2004. A significant proportion of this study was performed in the Department of Pathology. My sincere thanks goes to Professor Antero Kesäniemi, M.D., Ph.D., the Head of the Department of Internal Medicine, to Professor Timo Paavonen, M.D., Ph.D., and Professor Veli-Pekka Lehto, M.D., Ph.D., the present and former Heads of the Department of Pathology, who all made this study possible by providing facilities.

I wish to express my deepest gratitude to my supervisor Professor Vuokko Kinnula, M.D., Ph.D. (Helsinki University Hospital, Pulmonary Division), who introduced me to this research topic and shared with me her huge knowledge about human lung, oxidants and antioxidants. This project would have never been completed without her encouragement. I am grateful for the numerous learning opportunities which arose while combining biochemistry and medical aspects encountered in this study.

I want to thank Docent Sisko Anttila, M.D., Ph.D., and Dr. Anna-Liisa Levonen, M.D., Ph.D., for revising this thesis carefully and for their excellent comments. Dr. Ewen MacDonald deserves acknowledgements for revising language of this manuscript.

I also thank all former and present researchers of the radical team, seniors Katriina Kahlos, M.D., Ph.D., and Terttu Harju, M.D., Ph.D., deserve special thanks for they have made valuable work in creating working laboratory of oxygen radical research. Mirva Peltoniemi, M.Sc., Anne-Mari Svensk, M.D., Airi Puhakka, M.D., Leena Tiitto M.D. and Piia Markkanen, M.Sc., have shared recent years and provided help whenever needed.

Especially warm thanks goes to the pathologists, Docent Paavo Pääkkö, M.D., Ph.D., Docent Ylermi Soini, M.D., Ph.D., Docent Riitta Kaartenaho-Wiik, M.D., Ph.D., and Pasi Hirvikoski, M.D., Ph.D., for hours they have spent analysing lung biopsies and for their never-ending patience when teaching me the basic aspects of lung pathology.

The skilful and valuable assistance of Ms. Raija Sirviö, Ms. Satu Koljonen, Mr. Manu Tuovinen and Ms. Päivi Koukkula deserves sincere acknowledgement. I owe warm thanks to Ms. Terttu Niemelä, Ms. Marita Koistinen and Ms. Anne Salovaara for their help with many technical and practical problems, as well as to Ms. Seija Leskinen and other members of photography laboratory.

This thesis is mostly based on immunological methods, which could not have been performed without antibodies generously provided by Professor Sue Goo Rhee and Professor Sang Won Kang. Professor Kang deserves not only acknowledgements for the gifts of the antibodies but also for numerous comments and answers to my questions and concerns.

Special thanks goes to Professor Markku Savolainen, M.D., Ph.D., and Docent Pirjo Koistinen, M.D., Ph.D., and their research groups for their valuable co-operation throughout these years. In particular Docent Marjaana Säily, M.D., Ph.D., deserves extra thanks for her help. I'd like to thank all other members of the laboratory of Internal Medicine for sharing their time and know-how with me. The spirit of this laboratory is unique, even after the division into two physically distinct units. I want also thank the flexibility of Docent Petri Lehenkari, M.D., Ph.D. (Department of Surgery), during the last year.

From the bottom of my heart, I want to thank my family, Juha-Pekka, Juuso and Riina for being there for me. My mother and Muori get a special thanks for their support during all of my studies. My sister and her family, my father and his family as well as all other members of our family together with friends deserve loving thanks for all their encouragement and for having faith in me.

This work was financially supported by Finnish Tuberculosis Association Foundation, Finnish Cancer Society, The Finnish Cancer Society of Northern Finland, Paulo Foundation, Oulu University Hospital and University of Oulu, which all are gratefully acknowledged.



## Abbreviations

Ap1	Activator protein 1
Ap2	Activator protein 2
ATP	Adenosine triphosphate
RO <sup>•</sup>	Alkoxyl radical
AOE	Antioxidant enzyme
ARE	Antioxidant response element
bp	Base pair
BAL	Bronchoalveolar lavage
BSO	Buthionine sulfoximine
COPD	Chronic obstructive pulmonary disorder
CoA	Coenzyme A
cDNA	Complementary deoxyribonucleic acid
CuZnSOD	Copper zinc superoxide dismutase
Cys	Cysteine
CYP	Cytochrome P450 oxidase
Da	Dalton
DNA	Deoxyribonucleic acid
EM	Electron microscopy
EGF	Epidermal growth factor
ECSOD	Extracellular superoxide dismutase
GCL	Glutamate cysteine ligase
GPx	Glutathione peroxidase
GSH	Glutathione
GTP	Guanosine triphosphate
HBP	Heme binding protein
H <sub>2</sub> O <sub>2</sub>	Hydrogen peroxide
HOO <sup>•</sup>	Hydroperoxyl radical
OH <sup>•</sup>	Hydroxyl radical
Hif1	Hypoxia inducible factor 1
MSP	Macrophage stress protein
MnSOD	Manganese superoxide dismutase

mRNA	Messenger RNA
Met	Methionine
NKEF	Natural killer enhancing factor
NADH	Nicotinamide adenine dinucleotide
NADPH	Nicotinamide adenine dinucleotide phosphate
Nox	NADPH oxidase
NO <sup>•</sup>	Nitric oxide radical
NO <sub>2</sub> <sup>•</sup>	Nitric dioxide radical
NFκB	Nuclear factor kappa B
Nfr2	Nuclear factor erythroid 2 related factor 2
ORF	Open reading frame
OSF	Osteoblast specific factor
O <sub>3</sub>	Ozone
Prx	Peroxiredoxin
PMP	Peroxisomal membrane protein
ROO <sup>•</sup>	Peroxyl radical
OONO <sup>-</sup>	Peroxynitrite
PAG	Proliferation associated gene
PKC	Protein kinase C
ROS	Reactive oxygen species
RT-PCR	Reverse transcriptase – polymerase chain reaction
RNA	Ribonucleic acid
SDS-PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
O <sub>2</sub> <sup>-•</sup>	Superoxide anion radical
SOD	Superoxide dismutase
Sp1	Specificity protein 1
Trx	Thioredoxin
TDPX, TPx	Thioredoxin peroxidase
TrxR	Thioredoxin reductase
TAD	Transactivation domain
TGFβ	Transforming growth factor β
TNFα	Tumor necrosis factor α
XO	Xanthine oxidase

## List of original articles

This thesis is based on the following articles, which are referred to in the text by their Roman numerals. In addition some unpublished data is presented.

- I Kinnula VL, Lehtonen S, Kaarteenaho-Wiik R, Lakari E, Pääkkö P, Kang SW, Rhee SG & Soini Y (2002) Cell specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis *Thorax*. 57: 157-164.
- II Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG & Soini Y (2002) Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. *J Pathol* 196: 316-323.
- III Lehtonen ST & Svensk A-M, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, Säily M & Kinnula VL (2004) Peroxiredoxins, a novel new protein family in lung cancer. *Int J Cancer*. 111: 514-521.
- IV Lehtonen ST, Harju T, Kaarteenaho-Wiik R, Pääkkö P, Kang SW & Kinnula VL Cell-specific enhancement of Thioredoxin/Peroxiredoxin family in smoker's lung. Submitted.
- V Lehtonen ST, Markkanen P, Peltoniemi M, Kang SW & Kinnula VL (2005) Variable over-oxidation of peroxiredoxins in human lung cells in severe oxidative stress. *Am J Physiol Lung Cell Mol Physiol*. 288: L997-1001.

Original articles I, II, III and V have been used with permission from BMJ Publishing Group (I), John Wiley & Sons Ltd. (II), John Wiley & Sons, Inc (III) or American Physiology Society (V).



# Contents

Acknowledgements	
Abbreviations	
List of original articles	
Contents	
1 Introduction .....	13
2 Review of the literature .....	15
2.1 Reactive oxygen and nitrogen species .....	15
2.1.1 Hydrogen peroxide .....	15
2.1.2 Sources of reactive oxygen species .....	16
2.1.3 Effects of reactive oxygen species .....	18
2.2 Antioxidants .....	20
2.2.1 Superoxide dismutases .....	21
2.2.2 Catalase and glutathione peroxidases .....	21
2.2.3 Antioxidant related enzymes .....	22
2.3 Peroxiredoxins .....	23
2.3.1 Peroxiredoxins in different organisms .....	23
2.3.2 Catalytical mechanism of peroxiredoxins .....	24
2.3.3 Sulfiredoxin .....	26
2.3.4 Peroxiredoxin I .....	26
2.3.5 Peroxiredoxin II .....	27
2.3.6 Peroxiredoxin III .....	28
2.3.7 Peroxiredoxin IV .....	28
2.3.8 Peroxiredoxin V .....	28
2.3.9 Peroxiredoxin VI .....	29
2.3.10 Human peroxiredoxins .....	29
2.4 Human lung diseases associated with reactive oxygen species and antioxidant enzymes in human lung .....	30
2.4.1 Chronic obstructive pulmonary disease .....	31
2.4.2 Pulmonary sarcoidosis .....	31
2.4.3 Lung carcinomas .....	31
2.4.4 Malignant pleural mesothelioma .....	32

3 Aims of the study.....	33
4 Materials.....	34
4.1 Biopsies and bronchoalveolar lavage (I, II, III, IV).....	34
4.2 Cell cultures (I, II, IV and V).....	34
4.3 Antibodies (I, II, III, IV and V).....	35
5 Methods.....	36
5.1 Cell culture treatments (I, II, IV and V).....	36
5.2 Protein analysis.....	36
5.2.1 Immunohistochemistry (I, II, III and IV).....	36
5.2.2 Western blotting (I, II, III, IV and V).....	37
5.2.3 Immunoelectron microscopy (II).....	37
5.3 Transcript analysis.....	37
5.3.1 Extraction of RNA (III and V).....	37
5.3.2 Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) (III and V).....	37
5.4 Assessment of proliferation and apoptosis (II).....	38
5.5 Computational and statistical analysis.....	38
6 Results.....	39
6.1 Peroxiredoxins in healthy human lung (I, II, III and IV).....	39
6.2 Peroxiredoxins in pulmonary sarcoidosis (I).....	39
6.3 Peroxiredoxins in malignant mesothelioma and lung carcinomas (II and III).....	40
6.4 Peroxiredoxins, thioredoxin and thioredoxin reductase in smoker's lung and in chronic obstructive pulmonary disorder (IV).....	41
6.5 Peroxiredoxins in cultured cells (I, II, IV and V).....	41
6.6 Predicted gene structures and properties of peroxiredoxins.....	42
7 Discussion.....	44
7.1 Peroxiredoxins in normal human lung (I, II, III, IV and V).....	44
7.2 Peroxiredoxins in non-malignant diseases (I and IV).....	45
7.3 Peroxiredoxins in malignant diseases (II and III).....	45
7.4 Oxidation state of peroxiredoxins (IV and V).....	46
7.5 Regulation of peroxiredoxin expression (V).....	47
7.6 Methodological aspects (I, II, III, IV and V).....	47
8 Conclusions.....	50
9 References.....	51

# 1 Introduction

Oxygen (from two Greek words *oxy*=acid and *genes*=forming) was first described and named by Antoine Laurent Lavoisier (1743-1794), who is considered as one of the fathers of modern chemistry. However, this mysterious component of the air and water had puzzled researchers already prior to Lavoisier's innovative experiments. Already during the 18th century, it became obvious that this component was essential for life but later findings also suggested a dual role of oxygen as under certain circumstances it may also be toxic (Hensley & Floyd 2002). Current knowledge has further supported this dual roles i.e. oxygen is both essential and harmful to life. Both these roles are based on the reactivity of oxygen and this property has given rise to the entire concept of oxidation/reduction reactions.

During the last century, researchers noted that oxygen may form even more reactive molecules, termed reactive oxygen species (ROS). These include both radicals and other oxygen derivatives. Henry John Horstman Fenton (1854-1929) discovered that certain metals have the capability to improve the effect of hydrogen peroxide ( $H_2O_2$ ), one member of the ROS family. Today we know that this phenomenon is based on hydroxyl radical production from  $H_2O_2$  by using metal ion as a catalyst. This was the first important discovery utilising oxygen centred free radicals and even today the so called Fenton reaction is used in detoxifying certain chemicals. However, despite the possibility of utilising ROS in industrial processes and cleaning, it is now evident that ROS can be very harmful for living organisms. These molecules can disrupt the structure of all the critical cellular macromolecules, namely DNA, RNA, lipids, proteins and carbohydrates. Damage to DNA can lead to mutations, which can make cells susceptible to diseases like cancer. However, in processes like signal transduction even our own cells have learned to utilise ROS in controlling cell growth and proliferation and ROS have also a significant role in immune defence (Burdon *et al.* 1995, Thannickal & Fanburg 2000). Therefore their concentration in and outside the cells is strictly controlled by enzymatic systems, which include both ROS-producing and ROS-degrading enzymes, the latter being called antioxidant enzymes (AOEs). Classical AOEs contain superoxide dismutases (SODs, EC 1.15.1.1), catalase (EC 1.11.1.6) and glutathione peroxidases (GPxs, EC 1.11.1.9). Furthermore there are several AOE related proteins i.e. thioredoxins (Trxs), glutaredoxins (EC 1.20.4.1), and peroxiredoxins (Prxs, EC 1.11.1.15).

Prxs are small but abundant thiol-based enzymes that catalyse the degradation of  $H_2O_2$ , but they are also capable of decomposing other peroxides, such as certain oxidised lipids. They have been found in a wide variety of organisms from archea and eubacteria to humans. There are six distinct Prxs characterised in human cells, these being called Prxs I-VI, which share structural and functional similarities but have different tissue distributions (Jin *et al.* 1997, Kang *et al.* 1998a, Kang *et al.* 1998b, Seo *et al.* 2000, Okado-Matsumoto *et al.* 2000). Trxs and glutathione (GSH) provide the most important reducing power in the cells both having a broad substrate capacity. Reduction of Prxs is one task of Trxs: this is essential to restore the catalytical activity of Prxs.

In addition to their antioxidative role, Prxs and Trxs regulate signalling cascades affecting cell proliferation, differentiation, apoptosis and transcriptional regulation (Zhang *et al.* 1997, Kim *et al.* 2000, Sasagawa *et al.* 2001). Furthermore they can have an influence on the efficacy of drugs or other therapies based on ROS production (Park *et al.* 2000b, Chung *et al.* 2001). According to mouse mutant models, Prxs I, II or VI do not seem to be essential for normal development, but lack of Prx I or II causes haemolytic anaemia and Prx I seems to act as a tumour suppressor (Wang *et al.* 2003, Lee *et al.* 2003, Neumann *et al.* 2003). Lack of Prx VI renders especially the lung of mice susceptible to oxidant stress (Wang *et al.* 2003, Lee *et al.* 2003).

Prxs have been studied in human tissues only briefly, especially their expression and role in lung is unclear. There is however evidence for a connection between Prx levels and certain diseases; elevated Prx levels have been observed in some tumours but studies have mostly focused only to Prx I (Yanagawa *et al.* 1999, Yanagawa *et al.* 2000, Chang *et al.* 2001, Noh *et al.* 2001, Choi *et al.* 2002, Karihtala *et al.* 2003). Altered Prx levels have been also detected in neurological diseases characterised by oxidative stress, like Creutzfeld-Jacob disease, Alzheimer's disease, Pick's and Down syndromes (Kim *et al.* 2001b, Nicolls *et al.* 2003). There have been also proposals about their possible involvement to other diseases like atherosclerosis, but these issues need further clarification (Phelan *et al.* 2002). The role of Prxs in inflammatory diseases may be crucial, but at the beginning of this project there were no human studies on their involvement.

The lung provides an entry into the body for inhaled oxygen as well as bacteria, virus and many other harmful agents such as example pollutants or smoke. Oxygen and many chemicals give rise to ROS; furthermore the immune system of lung is dependent on active production of ROS by inflammatory cells. Therefore lung is continuously exposed to higher levels of ROS than most other tissues, which makes it especially important in the field of antioxidant research.

This study aimed at elucidating the expression, regulation and role of Prxs in normal human lung and during various lung disorders including pulmonary sarcoidosis, COPD, pleural mesothelioma and lung carcinomas.



## 2 Review of the literature

### 2.1 Reactive oxygen and nitrogen species

Reactive oxygen species can be defined as partially reduced oxygen intermediates. They contain free radicals like superoxide anion ( $O_2^{\bullet-}$ ), hydroxyl ( $OH^{\bullet}$ ), peroxy ( $ROO^{\bullet}$ ), alkoxy ( $RO^{\bullet}$ ) and hydroperoxy ( $HOO^{\bullet}$ ) radicals and non-radicals like hydrogen peroxide ( $H_2O_2$ ) and ozone ( $O_3$ ). In addition there are nitrogen-centred reactive species, which include peroxynitrite ( $OONO^{\bullet}$ ), nitric oxide ( $NO^{\bullet}$ ) and nitric dioxide ( $NO_2^{\bullet}$ ) radicals, whose formation is closely linked with ROS.

#### 2.1.1 Hydrogen peroxide

Hydrogen peroxide is a small molecule that easily passes through all membranes of the cell. In contrast to most other ROS, it is stable and can therefore be transported far from site of synthesis.  $H_2O_2$  is generated spontaneously or enzymatically by superoxide dismutation ( $O_2^{\bullet-} + 2 H^+ \rightarrow H_2O_2 + O_2$ ) and it can be converted to other ROS by Haber-Weiss reaction ( $O_2^{\bullet-} + H_2O_2 \rightarrow O_2 + OH^- + OH^{\bullet}$ ) or Fenton reaction ( $Fe^{2+} + H_2O_2 \rightarrow Fe^{3+} + OH^- + OH^{\bullet}$ ).

Even though  $H_2O_2$  is considered to be toxic, its role as second messenger became evident decades ago. Its concentration inside the cell fluctuates in phase with proliferation and it is thought to have a crucial role in maintaining normal cell growth and metabolism (Burdon *et al.* 1995).  $H_2O_2$  is produced in adipocytes after insulin exposure, but it can itself cause the same stimulatory effects even without the presence of insulin (May & de Haen 1979a, May & de Haen 1979b). Growth factors like transforming growth factor  $\beta$  (TGF- $\beta$ 1), platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) are known to elevate the  $H_2O_2$  concentration inside the cell and also some other signalling routes are known to associate with its concentration (Ohba *et al.* 1994, Li *et al.* 1995, Sundaresan *et al.* 1995, Bae *et al.* 1997, Bae *et al.* 2004). The mechanisms of this  $H_2O_2$  production are still unclear, but probably it is mediated by Rac-sensitive system as discussed later (Sundaresan *et al.* 1996, Bae *et al.* 2004).

There are two possible consequences of  $H_2O_2$  induction associated with signal cascades: binding of it or modification catalysed by it (Rhee 1999). Since the chemical structure of  $H_2O_2$  is so simple, it seems unlikely that it could be recognised and bound specifically by some protein during a specific signalling cascade. Probably the effect of  $H_2O_2$  is mediated by its ability to oxidize other molecules, especially the sulfhydryl moiety of cysteine (Cys) residues is thought to be an important target (Cooper *et al.* 2002, Poole *et al.* 2004). Cys exists in nature in several different oxidation states like thiols, thiolates, thiyl radicals, disulphides and sulphenic/sulphinic/sulphonic acids. Each state has its own properties, which affect the Cys containing protein's stability, redox-sensitivity, binding and catalytical properties.


$H_2O_2$  is not however capable of oxidizing all Cys residues, because pKa values of most protein Cys-SH groups are above 8 due to the surrounding amino acids. Oxidation by  $H_2O_2$  requires the pKa to be below 7. Nonetheless there are a number of candidate proteins possessing Cys-SH residues with low pKa values: Trx; protein disulfide isomerase; phosphatases; proteases and Prxs (Holmgren 1989, Freedman *et al.* 1994, Kortemme & Creighton 1995, Lohse *et al.* 1997, Rhee 1999). A common feature of these proteins is that they have two cysteines separated by two other residues (CxxC motif). In certain proteins, the carboxy-terminal Cys may be replaced by serine or threonine. Another possible target of  $H_2O_2$  modification is a methionine (Met) residue that can be oxidised to sulfoxide, but there is no evidence for signal transduction associated with Met.

### ***2.1.2 Sources of reactive oxygen species***

Molecular oxygen is the most important oxidant in nature and the high oxygen pressure present in the lung favours the formation of ROS. Like other tissues exposed directly to the atmosphere, the lung is constantly exposed to many extracellular components, i.e. not only ROS but other chemicals promoting chain reactions leading to ROS production. Additionally harmful components of cigarette smoke, pollutants, asbestos, irradiation and several chemotherapeutics evoke ROS exposure to lung (Kinnula & Crapo 2003). A brief overview of ROS production in the human lung is shown in figure 1.

The major intracellular source of ROS is aerobic energy metabolism. This is based on oxidative phosphorylation in which adenosine triphosphate (ATP) is formed as electrons originating from food sources are transferred to molecular oxygen ( $O_2$ ) by a multicomponent enzymatic system, in which cytochrome oxidase is the terminal electron donor. In eukaryotes, the oxidative phosphorylation takes place in the inner membrane of mitochondria by respiratory assemblies. However, during this transfer process, oxygen may be reduced only partially due to the sequential nature of reaction as shown in figure 2. The tendency towards partial reduction is a result of the molecular structure of  $O_2$ , which actually contains two unpaired electrons located in different orbitals and possessing different spins. This is not a common structure in other molecules or atoms and therefore it is difficult to find a matching molecule with electrons with opposite spins, and thus  $O_2$  is generally reduced by one electron at a time. Cytochrome oxidase itself maintains partially reduced oxygen in a tightly bound fashion, but some other


components of the electron transfer system (NADH ubiquinone reductase, succinate ubiquinone reductase or cytochrome c reductase) may leak electrons to oxygen (McLennan & Esposti 2000).



**Fig. 1. Major sources of ROS in human lung (modified from Kinnula & Crapo 2003 and Kinnula & Crapo 2004).**

One-electron reduction of  $O_2$  yields  $O_2^{\bullet-}$ , which can be converted to other ROS like  $H_2O_2$  or  $OH^{\bullet}$ . The amount of electrons leaking from the respiratory chain has been under debate, estimates varying from 0.1 % even to 2 % of total electron flow and even the whole concept of ROS generation in this way has been questioned (Boveris & Chance 1973, Imlay & Fridovich 1991, Forman & Azzi 1997). In addition to their location in the inner mitochondrial membrane, cytochrome oxidases are also located in endoplasmic reticulum and participate in oxidizing several compounds like steroids, xenobiotics and fatty acids (Zangar *et al.* 2004)

In addition to the mitochondrial respiratory chain, peroxisomal  $\beta$ -oxidation may also generate  $H_2O_2$  as a by-product (Kasai *et al.* 1989, Arnaiz *et al.* 1995). The first step it is the conversion of the fatty acyl-coenzyme A (-CoA) to *trans*-2-enoyl-CoA by acyl-CoA oxidase, which transfers electrons from the substrate to molecular oxygen, thus leading to  $H_2O_2$  generation (Schulz 1991). The leakage of  $H_2O_2$  out from peroxisomes may even be related to cell proliferation i.e. more  $H_2O_2$  is claimed to be released in highly proliferating cells (Oikawa & Novikoff 1995). On the other hand, the destruction of  $H_2O_2$  is very effective in peroxisomes, and thus there may be only minimal leakage of ROS to cytosol in general.



**Fig. 2. Schematic representation of the sequential reduction of molecular oxygen to water.**

There are also several other enzymes like NADPH oxidase (Nox), and xanthine oxidase (XO) that may produce ROS. Nox was originally defined as a phagocytic leukocyte specific enzyme, but subsequently similar oxidase complexes have been characterised in non-phagocytic cells such as vascular endothelial, smooth muscle cells and fibroblasts (Meier *et al.* 1991, Zulueta *et al.* 1995). In phagocytes, Nox is activated by chemokines or phagocytic particles, which induce assembly of cytosolic subunits (Rac2, p47<sup>phox</sup> and p67<sup>phox</sup>) with membrane bound compartments (p22<sup>phox</sup> and gp91) to generate  $O_2^{\bullet-}$  from  $O_2$  and NADPH. This so called respiratory burst leads to the release of ROS out of the cell, which is an important feature of immune defence against bacterial and fungal infections (Holmes *et al.* 1967). Released  $O_2^{\bullet-}$  may be converted to  $H_2O_2$ , which in turn is a substrate for myeloperoxidase that produces hypochlorous acid and other strong oxidants (Winterbourn *et al.* 2000).

In non-phagocytotic cells, endogenous ROS production by Nox has not been as extensively characterized. Several different homologues of gp91 are found in mammals with tissue specific expression and Rac2 has a homologue Rac1, while other subunits seem to be expressed widely in different cells. Several factors can initiate ROS production by Nox e.g. interleukin 1 $\beta$  (IL1 $\beta$ ), tumour necrosis factor  $\alpha$  (TNF $\alpha$ ), menadione, insulin, TGF $\beta$  or other growth factors (Nisimoto *et al.* 1988, Chiu *et al.* 2001, Li *et al.* 2002b, Baea *et al.* 2004, Chena *et al.* 2004, Talior *et al.* 2005).

XO, a key enzyme in purine catabolism, possesses the capability of generating  $O_2^{\bullet-}$ . It is located in cytoplasm, but is has been also detected on the outer surface of endothelial cells in an asymmetric manner (Rouquette *et al.* 1998). There are possibly several other systems also capable of generating ROS under certain circumstances. In addition, non-enzymatic reactions like radiolysis of water can result in the production of  $H^{\bullet}$  and  $OH^{\bullet}$  radicals.

### 2.1.3 Effects of reactive oxygen species

Reactive oxygen species can cause damage to living organisms via different targets as briefly reviewed in table 1. In multicellular organisms, ROS damages to DNA can be very harmful since they can cause mutations, which are then passed on to future cell

generations. However, more commonly ROS damage evokes apoptosis or necrosis, which can be very severe and extensive leading to major tissue damage.

In addition to H<sub>2</sub>O<sub>2</sub>, other ROS have also been linked to several signalling pathways and may have important regulatory functions. They have been associated with mitogen-activated kinase (MAPK), stress-activated protein kinase (SAPK) and protein kinase C (PKC) activities (Janssen-Heininger *et al.* 1999, Liu *et al.* 2000, Majumder *et al.* 2001). These provide tools for wide regulatory possibilities in cell growth, proliferation, apoptosis, differentiation and cellular metabolism.

*Table 1. Targets of ROS damage in the cells.*

Target	Damage	Primary consequence	Secondary consequence
DNA	Base damage	DNA repair	Cell cycle arrest
	Strand break	Mutations	Apoptosis Cancer or other diseases
RNA	Base damage	Translational errors	Alterations of cell growth and proliferation
	Strand break	Inhibition of protein synthesis	
Proteins	Oxidation of Cysteine or Methionine	Modified enzyme activity Modified protein stability Modified ion transport	Alterations of cell growth and proliferation
Lipids	Loss of unsaturation	Membrane damage Altered membrane permeability	Alterations of cell growth and proliferation
	Formation of reactive metabolites	Modified affinity of membrane bound proteins Chain reactions	
	Carbohydrates	Formation of reactive metabolites	
		Chain reactions	


Several transcription factors have been reported to be redox sensitive e.g. nuclear factor  $\kappa$ B (NF $\kappa$ B), activator protein 1 (Ap1) and specificity protein 1 (Sp1) (Toledano & Leonard 1991, Li *et al.* 1994, Ammendola *et al.* 1994). However, the participation of endogenously produced ROS in the activation of NF $\kappa$ B was recently questioned, as in TNF $\alpha$  stimulated cells, the activation occurs independently of Rac/NADPH oxidase and is terminated before the ROS concentration has become elevated (Hayakawa *et al.* 2003). This suggestion is supported by earlier observations indicating that H<sub>2</sub>O<sub>2</sub> does not activate NF $\kappa$ B in all cell types (Anderson *et al.* 1994, Bowie *et al.* 1997). Clearly further studies are needed to clarify the role and mechanism of the elevated ROS concentration during cell signalling processes.

Oxidative damage to lipids, proteins and especially to DNA is capable of activating the repairing machinery inside the cell. Oxidative DNA damage is predominantly repaired by base excision repair, nucleotide excision repair or direct ligation of single strand break. The first step in base excision repair is to remove oxidised nucleotides from

DNA by glycosylases, which cleave the bond between the base and the sugar. The resulting site without a base is removed by apurinic/apyrimidinic endonuclease and the subsequent gap is filled by DNA polymerase and ligated by DNA ligase (Kubota *et al.* 1996). Nucleotide excision repair removes a stretch of DNA, which is replaced after the synthesis of a new patch of DNA. This system requires the presence of several components including replication factors, DNA polymerases, ligases and nucleases.

## 2.2 Antioxidants

Reactive oxygen species are detoxified by antioxidants, which include both enzymatic and non-enzymatic systems e.g. molecules like vitamin C, vitamin E and carotenoids. The most important enzymatic systems are superoxide dismutases (SODs), catalase and the glutathione peroxidases. There are also other important systems participating in the defence against oxidants.



**Fig. 3. Overview of ROS production and catabolism.**

The first group comprises of enzymes associated with GSH including GSH S-transferases, glutamate-cysteine ligase (GCL, also known as  $\gamma$ -glutamyl-cysteine synthase) and glutaredoxins. The second group is formed by Trxs and Prxs, which are enzymes belonging to the thioredoxin system (Fig 3).

Oxidative stress may result not only from increased oxidant generation, but also from decreased antioxidant production or defective oxidative damage repair. Therefore the regulation of AOE expression is important and has been studied widely during recent years as have the effects of dietary antioxidants. Expression of several AOE is regulated by transcription factors Ap1, NFκB, hypoxia inducible factor 1 (Hif1), Sp1 and/or nuclear factor erythroid 2 related factor 2 (Nfr2). Regulatory areas of these genes contain the so-called antioxidant response element (ARE), which binds Nfr2 (Jaiswal 1994, Ren & Smith 1995, Jones *et al.* 1995, Mulcahy & Gipp 1995).

### ***2.2.1 Superoxide dismutases***

Superoxide dismutases decompose  $O_2^{\bullet-}$  to the less reactive  $H_2O_2$ . There are three different SODs in humans: cytosolic copper-zinc SOD (CuZnSOD); mitochondrial manganese SOD (MnSOD) and extracellular SOD (ECSOD). Mitochondrial metabolism is the major source of  $O_2^{\bullet-}$  and therefore it is not surprising that MnSOD located in mitochondrial matrix seems to be the most essential of the SODs. According to mouse models, MnSOD seems to be crucial since knockout mice die within three weeks after birth, while CuZnSOD and ECSOD knockout mice are nearly normal (Carlsson *et al.* 1995, Li *et al.* 1995).

MnSOD is dramatically induced by oxidative stress like exposure to cigarette smoke, while other SODs are less strictly regulated (Gilks *et al.* 1998). According to transfection studies in cultured cells, the overexpression of MnSOD induces resistance against hyperoxia, cigarette smoke, cytokines, irradiation or oxidants (St Clair *et al.* 1991, Hirose *et al.* 1993, Lindau-Shepard *et al.* 1994, St Clair *et al.* 1994).

### ***2.2.2 Catalase and glutathione peroxidases***

There are three classes of enzymes that detoxify  $H_2O_2$ , namely catalases, GPxs and Prxs. Catalase is located mostly in peroxisomes, but detected to some extent also in cytoplasm and mitochondria. It decomposes high concentrations of  $H_2O_2$  ( $H_2O_2 \rightarrow H_2O + \frac{1}{2}O_2$ ) with catalytical efficiency of about  $10^6 M^{-1}s^{-1}$  but it may also oxidize molecules like ethanol at low  $H_2O_2$  concentrations (Hillar *et al.* 2000). Catalase tightly binds heme and NADH/NADPH, though the latter compounds do not affect the enzymatic reaction but rather protect it from inactivation (Kirkman & Gaetani 1984). It has been recently suggested that catalase may have a dual role in oxidant systems as it has been shown to generate ROS in response to UVB radiation in keratinocytes (Heck *et al.* 2003). This observation gives another interesting perspective on the vulnerable balance of oxidants and antioxidants i.e. even the same enzyme may be both a protecting and damaging component depending on the prevalent circumstances.

GPxs are enzymes that receive their reducing power from glutathione, which in turn is reduced by glutathione reductase ( $H_2O_2 + 2GSH \rightarrow 2H_2O + GSSG$ ). The catalytical efficiency of GPxs is high, about  $10^8 M^{-1}s^{-1}$ . There are several GPxs, which have different locations (Brigelius-Flohe 1999). GPx1 and GPx2 are intracellular but GPx2 is found

only in the epithelium of gastrointestinal tract while GPx1 has a more widespread distribution in human tissues. GPx1 knockout mice develop normally and show no sensitivity to hyperoxia (Ho *et al.* 1997). However these mice suffer some abnormalities in their brain during cold-induced injury or stroke, pointing to a role for GPx1 in the regulation of cell death and inflammatory responses (Flentjar *et al.* 2002, Crack *et al.* 2003). GPx3 is extracellular and located mainly in plasma (Schwaab *et al.* 1998). GPx4 is widely expressed but its catalytical activity may be targeted to hydroperoxides integrated in membranes (Kelner & Montoya 1998). GPx5 is epididymis-specific secreted protein (Rigaudiere *et al.* 1992).

### 2.2.3 Antioxidant related enzymes

The most important reductants in cells are GSH and Trx. Trxs are small proteins of 10-12 kDa. Their major role is to reduce oxidised ribonucleotide reductase, Prxs and certain transcription factors like NFκB (Hayashi *et al.* 1993, Chae *et al.* 1994a). Trxs contain two Cys residues separated by two amino acids at their catalytical site. Sulphydryl groups of these Cys undergo reversible oxidation providing reducing power for the substrate. The formed disulphide of Trx is reduced by thioredoxin reductase (TrxR) with electrons originating from NADPH.

In human cells, Trx and TrxR can exist in two isoforms, one mitochondrial and the other cytosolic. The processed form of Trx may also be secreted out from the cell, where it binds to the outer plasma membrane (Balcewicz-Sablinska *et al.* 1991). A nuclear localisation has also been detected in certain cancer cells, even though there is no nuclear localisation signal sequence, but the small size of these proteins allows them to pass through nuclear pores by passive diffusion (Hirota *et al.* 1997, Grogan *et al.* 2000). The number of different Trxs or TrxR may however be even higher, as recently new Trx like homologues have been found but their catalytical relevance is still unclear. It is feasible that there might be several Trxs with different properties, e.g. different substrate affinities.

Due to Trx's important role as a reductant, they have several biological tasks. Trx itself is able to break down H<sub>2</sub>O<sub>2</sub>, thus it can be considered as an antioxidant (Spector *et al.* 1988). It has growth factor like properties, being able to stimulate growth of fibroblasts and certain tumour cells (Wakasugi *et al.* 1990, Oblong *et al.* 1994). Trxs also regulate kinase activity and thus can modify cell signalling in several different pathways and e.g. the apoptosis pathways (Saitoh *et al.* 1998). Trx is highly expressed in several carcinomas and this may be related to their developing resistance against anticancer treatments (Gasdaska *et al.* 1994, Kahlos *et al.* 2001a).

GSH belongs to a family of low molecular weight antioxidants since it is a tripeptide. The Cys residue of GSH is responsible for redox status and it nonenzymatically forms conjugates with reactive electrophilic compounds like aldehydes or peroxides. The rate limiting enzyme in GSH formation is GCL, which is formed from two subunits: the heavy subunit with catalytical activity and the light subunit with a regulatory role. The GSH and Trx systems were originally considered as two distinct systems, but there is a



clear interaction between them as GSH can inactivate Trx (Casagrande *et al.* 2002). Oxidation of GSH can be reversed by GSH reductase.

## 2.3 Peroxiredoxins

### 2.3.1 Peroxiredoxins in different organisms

Peroxiredoxins (Prxs) are a family of small proteins that catalyse the reduction of peroxides using their conserved Cys residues as catalytical centres. They do not require any co-factors, unlike the heme-dependent catalase and the selenium-dependent GPxs. The best characterised enzymes of the Prx family are the alkyl hydroperoxide reductases (Ahp) from *Escherichia coli* and *Salmonella typhimurium* (Greenberg & Demple 1988, Jacobson *et al.* 1989). They were characterised as protectors of DNA against oxidative injury and they use NADH or NADPH as their reducing agent, but act independently of GSH.

There are five different Prxs in the yeast *Saccharomyces cerevisiae*, namely thiol specific antioxidant enzyme 1 (Tsa1, known also as cytosolic thioredoxin peroxidase I cTPx I), cTPx II, cTPx III, nTPx and mTPx (Chae *et al.* 1993, Verdoucq *et al.* 1999, Jeong *et al.* 1999, Lee *et al.* 1999, Pedrajas *et al.* 2000, Park *et al.* 2000a). Tsa1 is the most abundant Prx in the cytoplasm and mTPx is located in mitochondria. Genetic studies carried out in *S. cerevisiae* showed that Tsa1 is not essential for normal growth under anaerobic conditions (Chae *et al.* 1993). However, under aerobic conditions, the growth rate of a mutant yeast lacking *Tsa1* becomes depressed especially under oxidative pressure. The importance of Tsa1 as antioxidant is further confirmed by the fact that its expression is upregulated in normal yeast if they are shifted from anaerobic to hyperaerobic conditions (Kim *et al.* 1989).

In addition to microorganisms, Prx family members have been found in mammals and plants (Chae *et al.* 1994b, Baier & Dietz 1996). There may be several different Prxs present in the same organism, up to eight in some plants with some being targeted to mitochondria and some to chloroplasts, where they are important in protecting proteins against oxidative injury and in maintaining normal photosynthesis (Baier & Dietz 1999). Some Prxs have a protective role also against reactive nitrogen species (Wong *et al.* 2002, Sakamoto *et al.* 2003).

In human cells, there are six different Prxs, which are named Prx I-VI. Prxs were originally characterized from mammalian cells mostly recognized for properties other than their antioxidant effects. They have been identified for example as proliferation associated gene (PAG), natural killer enhancing factor (NKEF), macrophage 23 kDa stress protein (MSP23), peroxisomal membrane protein (PMP), torin and 23 kDa heme binding protein (HBP23) (Ishii *et al.* 1993, Shau *et al.* 1994, Iwahara *et al.* 1995, Yamashita *et al.* 1999, Harris *et al.* 2001).


There is now convincing evidence for a role for H<sub>2</sub>O<sub>2</sub> in cellular signalling, but the regulation of its concentration is poorly understood. As the concentrations needed for signalling are thought to be low, it seems unlikely that catalase could be the enzyme responsible for H<sub>2</sub>O<sub>2</sub> removal. The catalytical efficiency of Prxs is weaker than that of

catalase or GPxs, but the optimal  $H_2O_2$  concentration for Prxs is relatively low, and for this reason, these enzymes have been considered as potential regulators of endogenously produced  $H_2O_2$ . According to overexpression studies, cytosolic Prxs are known to break down  $H_2O_2$  generated as second messengers of  $TNF\alpha$  or growth factors and Prx III participates in apoptosis signalling in mitochondria (Kang *et al.* 1998b, Kang *et al.* 2004, Chang *et al.* 2004a).

Human Prx genes have been poorly characterized, but the murine genes have been analysed in some detail. Some properties of human Prxs are summarised in table 2. In addition to the indicated chromosomal locations, there are several pseudogenes found in the human genome e.g. in positions 9p22, 13q12 and 4q35.2.

### 2.3.2 Catalytic mechanism of peroxiredoxins

Peroxiredoxins can be divided into three categories according to their structure and catalytic mechanism, namely 2-Cys Prxs, atypical 2-Cys Prxs and one cysteine (1-Cys) Prxs. Human Prxs I-IV belong to the first category, Prx V is an atypical 2-Cys Prx and Prx VI is 1-Cys Prx (Kang *et al.* 1998a, Kang *et al.* 1998b).




**Fig. 4. Model of typical 2-Cys Prx catalytic mechanism partially modified from Wood and co-workers (2002).**

2-Cys Prxs seem to be mostly present as homodimers, but they may also form heterodimers and several dimers may further group together to form even decamers

(Schroder *et al.* 2000, Harris *et al.* 2001, Wood *et al.* 2002). Prxs oligomerisation is dependent on ionic strength, pH, magnesium/calcium concentrations and most of all, the redox state of the active Cys. It has been suggested that the peroxidase reaction of all Prxs is initiated when the thiol group of cysteine (-SH) attacks peroxide (figure 4).

The thiol group becomes itself sulphenic acid (-S-OH), which is highly unstable and quickly forms either a disulphide bridge (-S-S-) with another thiol or is converted to sulphinic acid (-SOOH) or even sulphonic acid (-SOOOH). Disulphide bridges are generally reduced by thioredoxin or possibly by glutathione, but these reductants are not able to reduce sulphenic acid forms of cysteines. Previously these so called over-oxidised forms were thought to be irreversible, but recent data suggests that they are reduced by a protein called sulfiredoxin (Biteau *et al.* 2003, Woo *et al.* 2003). The catalytical mechanism of Prxs exhibits similarities to other thiol proteins (Poole *et al.* 2004).

Atypical 2-Cys Prxs probably form an intramolecular disulphide bridge instead of dimerization as shown in figure 5 (Seo *et al.* 2000). 1-Cys Prxs bind some other molecule than Prx.



**Fig. 5. Model of atypical 2-Cys Prx catalytical mechanism as proposed by Seo and co-authors (2000).**

Prxs can undergo a direct interaction with cyclophilin A. Cyclophilins are abundant proteins first characterised for their ability to act as a cyclosporine A receptor. They have *cis-trans* isomerase activity fitting with their proposed role as chaperones (Ivery 2000). Additionally cyclophilins seem to act as mediators in signalling and have growth factor like effects after oxidant exposure (Jin *et al.* 2000).

### 2.3.3 *Sulfiredoxin*

Sulfiredoxin was recently characterized from budding yeast as an enzyme with an ability to reduce Cys-SOOH (Biteau *et al.* 2003). Sulfiredoxin, like Trxs and Prxs, is a thiol protein whose activity is based on its Cys residue. It has conserved homologues in higher eucaryotes, but they are so far poorly characterized. No homologue has been found in procaryotes, except in certain cyanobacteria. Bacterial Prxs are indeed much less sensitive to overoxidation, as they generally have a slightly different structure at their C-terminal end. Budding yeast has both sensitive and insensitive Prxs for overoxidation and sulfiredoxin was shown especially to affect the activity of sensitive forms. Yeast sulfiredoxin was proposed to act both as a phosphotransferase and a thioltransferase, as ATP hydrolysis, Mg-ion and dithiothreitol was essential for the function. Mammalian sulfiredoxins seem to have different mechanisms of action as they prefer using GTP hydrolysis as power and Trx or GSH as co-factor (Chang *et al.* 2004b). The substrate specificity of sulfiredoxins is still unclear but they cannot rescue the overoxidised forms of atypical 2-Cys Prxs or 1-Cys Prxs (Woo *et al.* 2004) but on the other hand, their activity may not be targeted only to Prxs, but they may be involved in repairing several other damaged proteins as well.

### 2.3.4 *Peroxiredoxin I*

Human Prx I is a 22 kDa protein expressed ubiquitously throughout the body. It has been known by the names PAG-A, NKEF-A and thioredoxin peroxidase A (TpX-A or TDPX-A) (Prosperi *et al.* 1993, Prosperi *et al.* 1994, Shau *et al.* 1994, Pahl *et al.* 1995). Its mouse homologue is known also as MSP23 or osteoblast specific factor (OSF-3) (Ishii *et al.* 1993, Kawai *et al.* 1994). It has been considered to be a cytoplasmic enzyme, but a recent report has suggested additionally nuclear, mitochondrial and peroxisomal locations (Immenschuh *et al.* 2003). Its expression is induced by serum, oxidative stress and in some cases by H<sub>2</sub>O<sub>2</sub> but not in every cell type (Ishii *et al.* 1993, Prosperi *et al.* 1993, Prosperi *et al.* 1994, Kim *et al.* 2000). In cultured murine cells, Prx I expression is cell cycle dependent being highest at the S phase (Prosperi *et al.* 1998). This has not been observed in human cells, but instead Prx I phosphorylation is affected by cell cycle state so that it occurs during mitosis (Chang *et al.* 2002). This Cdc2 mediated phosphorylation on threonine 90 inhibits Prx I activity, which may have an important role in regulating the H<sub>2</sub>O<sub>2</sub> concentration during mitosis. However, only a fraction of Prx I is phosphorylated, which may in theory even result in a H<sub>2</sub>O<sub>2</sub> gradient inside the cell.

Prx I expression is upregulated in the rat lung during late gestation being highest at the time of birth (Kim *et al.* 2001a). This upregulation seems to occur at the translational level as the amount of mRNA is even lowered. In newborn rats, the expression is lowered within a few days to adult levels but can be again induced by hyperoxia. Prx I expression has also been studied in the fetal baboon lung, but only at the mRNA level, where it remained constant during the last trimester (Das *et al.* 2001). The amount of mRNA was however increased after birth in an oxygen dependent manner via PKC regulation. Sodium arsenate, an agent inducing oxidative stress, increases the level of Prx I

expression as well acting via a PKC $\delta$  mediated mechanism in murine osteoblasts (Li *et al.* 2002a). Very little is known about the details of Prx I induction, but transcription factor Nrf2 is essential in this induction response, at least in mouse macrophages (Ishii *et al.* 2000).

In cultured cells, the overexpression of Prx I protects cells against apoptosis induced by H<sub>2</sub>O<sub>2</sub> but not by other agents such as doxorubicin (Berggren *et al.* 2001). Murine Prx I has been shown to interact with the SH-3 and kinase domains of c-abl and to reverse c-abl's cytostatic effects (Wen & Van Etten 1997). It also interacts with the Myc Box II (MBII) region of the c-Myc transactivation domain (TAD), which is highly conserved among all Myc oncoprotein members (Mu *et al.* 2002). Prx I and c-Myc also confer resistance to oxidative stress. In contrast, Prx I inhibits tumorigenesis by c-Myc overexpressing fibroblasts and cause a selective loss of c-Myc target gene regulation, which suggests a role for Prx I as a tumor suppressor. This is also supported by results from a transgenic mouse model: *Prx I* knockout mice develop lymphomas, sarcomas and carcinomas (Neumann *et al.* 2003). Mice lacking Prx I suffer also from haemolytic anaemia, which shows the importance of Prx I for erythrocyte antioxidative defence (Immenschuh *et al.* 2003).

### 2.3.5 Peroxiredoxin II

Prx II (22 kDa) is also known as TDPX-1 or -B, TpX-B, PAG-B, NKEF-B, protector protein (PRP), TSA, torin and calpromotin (Harris & Naeem 1981, Kim *et al.* 1988, Moore *et al.* 1990, Prosperi *et al.* 1994, Shau *et al.* 1994). It is very similar to Prx I in the structure, subcellular location and catalytical properties (Lim *et al.* 1994). Prx II has some anti-apoptotic characteristics as its overexpression leads to resistance against cisplatin, irradiation, serum starvation, ceramide and etoposide (Zhang *et al.* 1997, Park *et al.* 2000b, Chung *et al.* 2001). Manipulations of Prx II levels have also shown that Prx II inhibits NF $\kappa$ B activation after TNF $\alpha$  or H<sub>2</sub>O<sub>2</sub> treatment and they have also shown the importance of the H<sub>2</sub>O<sub>2</sub> concentration in several signalling cascades downstream to TNF $\alpha$  (Kang *et al.* 1998b, Kang *et al.* 2004). Artificial Prx II down-regulation in cultured cells makes the cells more susceptible to apoptosis by cisplatin treatment, and in that way it can be considered as a chemosensitiser, which makes it extremely important in the cancer treatment strategies (Yoo *et al.* 2002).

Prx II expression in the rat lung during perinatal period is constant at the protein level but transcriptional induction is observed at the time of the birth (Kim *et al.* 2001a). The regulation of Prx II expression is poorly characterised, but it does not seem to be altered by H<sub>2</sub>O<sub>2</sub> (Seo *et al.* 1999, Kim *et al.* 2000). Prx II expression is induced by ultraviolet B radiation in rat skin and by a high glucose content in glomerular mesangial cells (Lee *et al.* 2000a, Morrison *et al.* 2004).

Prx II is an abundant protein in erythrocytes, *Prx II* knockout mice develop hemolytic anemia (Lee *et al.* 2003). It binds membrane proteins or membranes by its C-terminus (Moore & Shriver 1997, Cha *et al.* 2000).

### **2.3.6 Peroxiredoxin III**

Prx III is a mitochondrial enzyme and it may have a significant role in the protection against ROS produced by aerobic metabolism. In mouse, it is known by the names antioxidant protein 1 (AOP1) and Mer5 (Tsuji *et al.* 1995). Prx III has a mitochondrial localisation signal sequence that is cleaved. Antisense experiments performed on murine cells have revealed that it is essential for normal mitochondrial function as its depletion decreases mitochondrial mass, membrane potential and affects mitochondrial morphology (Wonsey *et al.* 2002). Prx III activity is negatively regulated by protein synthesis inhibitor Abrin A-chain (ABRA), which is an inducer of apoptosis (Shih *et al.* 2001). This interaction can influence the ROS levels in the mitochondria thus resulting in the release of cytochrome c that activates the caspase cascade. Cyclophilin 18 binds and stimulates its activity, but the significance of this interaction is not clear as they have different subcellular localizations (Jaschke *et al.* 1998). *Prx III* is regulated by c-Myc and on the other hand it is required for c-Myc mediated proliferation, transformation and apoptosis (Wonsey *et al.* 2002).

### **2.3.7 Peroxiredoxin IV**

Prx IV, which is also called antioxidant enzyme 372 (AOE372) and TPx related activator of NF- $\kappa$ B (TRANK), is partly extracellular and the intracellular precursor is proposed to be inactive (Okado-Matsumoto *et al.* 2000). The location and the role of Prx IV have been under debate due to conflicting reports, but probably the intracellular or membrane bound form of 31 kDa is cleaved to the secreted form of 27 kDa in certain but not in all cell types. In cultured rodent cells, it has been detected only in the intracellular space, where its overexpression prevents ROS production by p53 or EGF (Wong *et al.* 2000). Prx IV seems to have cytokine-like properties, as Prx IV exposure of the cells induces iNOS by receptor-mediated mechanism (Haridas *et al.* 1998). It also activates c-Jun N-terminal kinase and induces proliferation in fibroblasts.

Prx IV can bind to heparan sulphate, which is located on the cell surface. It has been proposed that Prx IV is anchored on the extracellular surface, where its function is regulated by extracellular signals like redox status (Okado-Matsumoto *et al.* 2000). Prx IV may have an effect on rat spermiogenesis during membrane rearrangement as cleaved and membrane bound forms seem to be present in different phases (Sasagawa *et al.* 2001).

### **2.3.8 Peroxiredoxin V**

Prx V is the smallest (22 kDa and cleaved form 17 kDa) but most widely subcellularly distributed of the Prxs; it is cytoplasmic, nuclear and organellar (Knoops *et al.* 1999, Seo *et al.* 2000, Zhou *et al.* 2000). It was first identified as a gene that is downregulated in adenovirus-infected cells and it has been known by names like antioxidant enzyme 166

(AOE166), PMP20 or ARC1 (Wattiez *et al.* 1999, Kropotov *et al.* 1999). It has the capability to bind DNA and to repress RNA polymerase III catalysed transcription *in vitro*, but the *in vivo* significance of these abilities remains unclear (Kropotov *et al.* 1999). In mouse, there are different transcripts produced tissue-specifically but some of them are possibly translationally inactive (Lee *et al.* 2000b, Sparling & Phelan 2003). Prx V expression is induced by calcium in keratinocytes but in other cell types the regulation is unclear (Seo *et al.* 2002). Also Prx V overexpression prevents p53 induced ROS generation and apoptosis, furthermore when targeted to the nucleus it can protect DNA (Zhou *et al.* 2000, Banmeyer *et al.* 2004). Downregulation of Prx V increases the amount of etoposide-induced DNA double-strand breaks (Kropotov *et al.* 2004). In the rat lung inflammation increases Prx V transcription pointing to protective role for Prx V in lung during inflammatory processes (Knoops *et al.* 1999). Prx V is the only one of human Prxs known to act also as a peroxynitrite reductase (Dubuisson *et al.* 2004).

### 2.3.9 Peroxiredoxin VI

Prx VI has been known by names AOP2, ORF6, phospholipase A<sub>2</sub> (PLA2), KIAA0106 and non-selenium glutathione peroxidase (Nagase *et al.* 1995, Jin *et al.* 1997, Kim *et al.* 1997, Kim *et al.* 1998, Phelan *et al.* 1998). Prx VI is cytosolic, but it differs remarkably from Prxs I and II as it belongs to the group of 1-Cys Prxs and it is not reduced by Trx but rather GSH (Fisher *et al.* 1999, Fratelli *et al.* 2002, Manevich *et al.* 2004). It has not only peroxidase but also possesses phospholipase A<sub>2</sub> activity and has been implicated in repairing oxidised lipids (Manevich *et al.* 2002). Animal models have indicated that it is possibly the most important Prx in the lung and also highly expressed there (Kim *et al.* 1998, Kim *et al.* 2002, Wang *et al.* 2003, Wang *et al.* 2004).

*Prx VI* knock-out mice have a shorter life span, severe tissue damage and increased protein oxidation compared to normal mice (Wang *et al.* 2003). Also knock-in mice have been developed and they have a decreased H<sub>2</sub>O<sub>2</sub> accumulation (Phelan *et al.* 2003), but the relevance of this finding to the normal life span or diseases is not clear, even though oxidative stress in the rat lung is known to induce Prx VI expression (Kim *et al.* 2003). Adenovirus mediated transfer of *Prx VI* into murine lung protects its lung against hyperoxic injury thus supporting results obtained from transgenic animals (Wang *et al.* 2004).

### 2.3.10 Human peroxiredoxins

Increased oxidative stress in tissues and cells has to be combated by increased antioxidant capacity. Indeed, Prx expression is known to be increased in several different carcinomas. One preliminary study performed in two different cell lines originating from human lung and in four homogenate samples of lung carcinoma indicated that Prx I expression might be altered in lung carcinoma (Chang *et al.* 2001). Prx I expression is high also in thyroid, oral and breast carcinomas (Yanagawa *et al.* 1999, Yanagawa *et al.* 2000, Noh *et al.* 2001, Karihtala *et al.* 2003). Mouse models support the idea for an

important role for Prxs in several diseases. Prx level alterations have been also noted in Creutzfeld-Jacob disease, Alzheimer's disease, Pick's and Down syndromes (Kim *et al.* 2001b, Nicolls *et al.* 2003, Sanchez-Font *et al.* 2003). The properties of human Prxs are summarised in table 2.

Table 2. Properties of human Prxs.

Prx	Length (amino acids)	Calculated size (kDa)	Cleaved form (kDa)	Genebank accession number	Interactions with	Chromosome
I	199	22	-	GI 440306	C-myc Heme c-Abl Macrophage migration inhibitory factor Cyclophilin	1p34.1
II	198	22	-	GI 440308	Membrane Cyclophilin	19p13.2
III	256	28	21	GI 682748	ABRA Cyclophilin	10q25-26
IV	271	31	27	GI 799381	Heparin Cyclophilin	Xp22.11
V	214	22	17	GI 6103724	DNA Cyclophilin	11q13
VI	224	25	-	GI 285949	Cyclophilin	1q25.1

## 2.4 Human lung diseases associated with reactive oxygen species and antioxidant enzymes in human lung

ROS have been linked to several both non-malignant and malignant lung diseases e.g. obstructive lung diseases (asthma and chronic obstructive pulmonary disease COPD), interstitial lung diseases (granulomatous diseases and idiopathic pneumonias), carcinomas, dysplasias and respiratory distress syndrome (Saetta *et al.* 2001, Kinnula & Crapo 2003, Kinnula & Crapo 2004, Kinnula *et al.* 2004). Cigarette smoke contains free radicals and other ROS, but it also activates inflammatory cells to produce the ROS and thus a high proportion of patients suffering lung disease will have a smoking history.

Normal human lung is well protected against ROS. The epithelial lining fluid contains GSH, vitamin E, vitamin C and several important proteins like metal binding transferrin (Cantin *et al.* 1987, Cantin *et al.* 1990, Kinnula *et al.* 2004). Furthermore, several AOE including CuZnSOD, MnSOD, ECSOD and catalase are expressed in the epithelium of the human airways (Marklund 1984, Oury *et al.* 1996, Lakari *et al.* 1998, Lakari *et al.*



2000). All of these enzymes are detected in both bronchial and alveolar epithelium. MnSOD and ECSOD are also located in macrophages. All of these enzymes, except MnSOD, can be found in vascular endothelial cells and MnSOD and CuZnSOD are also found in fibroblasts.

### ***2.4.1 Chronic obstructive pulmonary disease***

One common disease generally caused by smoking is COPD. It is a severe and progressive disease characterized by inflammation in airways, obstruction of peripheral airways and emphysema. It consists of morphological changes in both central and peripheral airways. Histopathological changes include increased amounts of macrophages, neutrophils, Goblet cells and enlarged mucous secreting glands, but fewer ciliated cells. Tissue proteolysis results in loss of lung elasticity and reduces the amount of alveolar epithelial cells. Oxidant stress plays an important role in injury and the inflammatory responses of COPD and thus the regulation of antioxidant enzymes may have a crucial effect on the initiation and progression of this disease (Ichinose *et al.* 2000, Paredi *et al.* 2000, Saetta *et al.* 2001, MacNee 2001, Langen *et al.* 2003).

### ***2.4.2 Pulmonary sarcoidosis***

Sarcoidosis is a granulomatous disorder of unknown origin. In addition to granulomas, it is characterised by inflammation. It is capable spreading over several organs and its grade can vary from spontaneous recovery to fatal. ROS production especially from inflammatory cells increases the oxidative stress during sarcoidosis and presumably can affect the pathogenesis of this disease (Calhoun *et al.* 1988). MnSOD is highly expressed in granulomas and is upregulated also in bronchoalveolar lavage (BAL) of patients with sarcoidosis (Lakari *et al.* 1998, Lakari *et al.* 2000)

### ***2.4.3 Lung carcinomas***

Lung carcinomas can be divided to small cell and non-small cell lung carcinomas. Small cell carcinomas are usually aggressive but sensitive to anti-cancer drugs. Non-small cell carcinomas include adenocarcinomas, large cell carcinomas and squamous cell carcinomas, which are often resistant to drugs. In addition to smoking, asbestos exposure is considered as a risk factor for their promotion (Rahman *et al.* 1977, Mossman & Gee 1989). ROS are important in initiation, progression and even treatment of lung carcinomas as ROS affect mitogenic signalling, cell motility, tumour invasiveness and apoptosis (Behrend *et al.* 2003, Knaapen *et al.* 2004). In particular, p53 mediated apoptosis and hypoxia-inducible factor stabilisation with resulting angiogenesis are important ROS sensitive mechanisms associated with tumour initiation and progression (Green & Reed 1998, Chandel & Schumacker 2000). The levels of antioxidant enzymes

in lung cancer are variable, but there is evidence that at least the Trx-system is highly elevated in this tumor and this is claimed to have an association to patient prognosis (Kahlos *et al.* 2001a, Raffel *et al.* 2003).

#### ***2.4.4 Malignant pleural mesothelioma***

Malignant pleural mesothelioma is often attributable to asbestos exposure. Asbestos causes DNA strand breaks and damage to cells (Jackson *et al.* 1987, Kamp *et al.* 1992). Even though it is rather rare tumour, its resistance to therapeutics makes it an important target of cancer research. Mesothelioma contains elevated levels of several AOE's including MnSOD, catalase and GCL and Trx (Kahlos *et al.* 1998, Kahlos *et al.* 2001b, Järvinen *et al.* 2002, Kinnula & Crapo 2004).

### **3 Aims of the study**

The purpose of the study was to understand the mechanisms of Prx expression, action and regulation in human lung. The more specific aims of the study were:

1. To determine the cell specific expression and subcellular localization of Prxs at the protein level in normal human lung and in various cultured human lung cell lines including malignant A549 cells and five different mesothelioma cell lines , and non-malignant bronchial Beas2B cells and mesothelial cells Met5A.
2. To assess the cell specific expression of Prxs during inflammation (sarcoidosis).
3. To examine Prx during different malignancies of the lung (especially squamous cell carcinoma and adenocarcinoma) and pleura (malignant pleural mesothelioma).
4. To study the responses of Prx, Trx and TrxR expression to smoking and in patients with COPD.
5. To assess the regulation of Prxs at the transcriptional and translational levels, and the post-translational oxidation state in lung cells exposed to oxidants or cytokines that are relevant in human lung diseases.

## **4 Materials**

### **4.1 Biopsies and bronchoalveolar lavage (I, II, III, IV)**

Biopsies used were retrieved from the files of the Department of Pathology. Clinical information of all patients was received from patient records from Oulu University Hospital. Parenchymal biopsy specimens with sarcoidosis from ten patients and four control samples with normal histopathology from non-smokers were studied by immunohistochemistry (I). Samples with malignant mesothelioma from 36 patients and four apparently normal control samples of pleura (II), 92 carcinoma samples from patients with lung cancer and six histopathologically normal controls (III) were analysed by immunohistochemistry. Fifteen patients with COPD, 9 nonsmoking and 17 smoking controls (IV) were studied by immunohistochemistry so that a central and peripheral sample of each patient were analysed.

Tissue carcinoma samples from five patients with adenocarcinoma and six with squamous cell carcinoma were analysed by Western and/or RT-PCR (III). Seven peripheral tissue samples from patients with COPD and three healthy controls were studied by Western analysis (IV). The cells from the bronchoalveolar lavage were studied from four patients with sarcoidosis and two controls (I). The controls were suffering from minor respiratory symptoms, but their BAL cell profile was normal. Bronchoscopic examinations have been conducted as differential diagnostic investigations under local anesthesia.

Usage of patient samples in this study has been approved by Ethics committee of Northern Ostrobothnica District and TEO as required.

### **4.2 Cell cultures (I, II, IV and V)**

Malignant lung adenocarcinoma cell line A549 derived from type II pneumocyte, non-malignant SV40 transformed bronchial epithelial Beas 2B cells and non-malignant SV40 transformed pleural mesothelial Met5A cells have been purchased from American Type Culture Collections or from National Cancer Institute (Laboratory of Human

Carcinogenesis, Dr Harris, Bethesda, USA). These cell lines were selected as they are well characterised and studied. Five different continuous mesothelioma cell lines (M14K, M24K, M25K, M28K and M38K) have been originally established from the tumour cells of five patients with untreated malignant mesothelioma (Pelin-Enlund *et al.* 1990).

### **4.3 Antibodies (I, II, III, IV and V)**

Polyclonal anti-Prx antibodies were kindly provided by Professor Sue Goo Rhee (Laboratory of Cell Signaling, National Institute of Health, Bethesda, MD, USA) and Professor Sang Won Kang (Ewha Womans University, Seoul, Republic of Korea). They are well characterised antibodies and have high specificity (Jin *et al.* 1997, Kang *et al.* 1998a, Kang *et al.* 1998b, Seo *et al.* 2000). Monoclonal anti- $\beta$ -actin antibody (Sigma-Aldrich) has been used to normalize the detection. Trx and TrxR antibodies (Sigma-Aldrich) were used in some cases. Polyclonal MnSOD and GCS heavy chain antibodies were generous gifts from Professor J.D. Crapo and T. Kavanagh and they were used as controls of cell culture treatments. Ki-67 antibody (Zymed) was used to estimate the proliferation state of cells (II) since Ki-67 is expressed only in proliferating cells but is missing from resting cells (Gerdes *et al.* 1984).

## **5 Methods**

### **5.1 Cell culture treatments (I, II, IV and V)**

The cells were cultured according to the suppliers' instructions. Cultured A549 and Beas2B cells were exposed to variable concentration of H<sub>2</sub>O<sub>2</sub> to create direct oxidative stress and to menadione or cisplatin to cause endogenous ROS production (IV and V). TNF $\alpha$  was used because it is an important cytokine and is known to upregulate MnSOD expression. TGF $\beta$  was selected as it is a growth factor whose function is associated with ROS and it downregulates GCL expression. BSO was used to deplete GSH, which affects the redox state of the cell. Generally cells were passaged the day before the initiation of exposure so that growth phase had started. The agent was added to normal growth medium and cells were cultured there for 1-72 hours. For some overoxidation analysis, the cells received a 30-60 min pulse of H<sub>2</sub>O<sub>2</sub>, after which the medium was replaced with fresh growth media.

In the serum starvation and stimulation assay, the cells were passaged normally and on the next day the normal medium was replaced with medium containing no serum. Cells were cultivated for 72 h to synchronise the cells, after which the medium was replaced with normal media.

### **5.2 Protein analysis**

#### ***5.2.1 Immunohistochemistry (I, II, III and IV)***

The tissues were fixed in 10 % formalin and embedded in paraffin after dehydration. Four  $\mu$ m thick sections were cut from paraffin embedded biopsies and processed routinely through xylene and ethanol series. Immunostainings were done by Histostain™ –Plus Kit (Zymed Laboratories Inc., USA) according to the manufacturer's instructions. This staining is based on biotinylated secondary antibody in conjunction with streptavidin peroxidase. Counterstaining was performed with Mayer-hematoxylin. Stain intensities have been evaluated semiquantitatively in collaboration with two or three pathologists.

Negative controls containing PBS or isotype control serum from non-immunised host animal instead of primary antibody were prepared in each staining series and confirmed to be negative. Dilutions of Prx antibodies varied slightly in different series due the different lots used.

### ***5.2.2 Western blotting (I, II, III, IV and V)***

For Western analysis, the biopsies were stored in liquid nitrogen and cultured cells were trypsinated and the cell pellets were stored at -70°C after washing with PBS. Western blotting was used to detect Prxs after routine SDS-PAGE or after non-reducing electrophoresis. Non-reducing electrophoresis was performed as standard SDS-PAGE, except that the sample buffer contained no  $\beta$ -mercaptoethanol. This left the subunits of the dimeric forms associated together, since to break the disulphide bridge would require addition of a strong reductant. An enhanced chemiluminescence system was used for detection.

### ***5.2.3 Immunoelectron microscopy (II)***

Immunoelectron microscopy was performed to study the subcellular localisation of Prxs in lung cells. Cultured cells were fixed in 4 % paraformaldehyde, immersed with 2.3 M sucrose and frozen. Cryosections were treated with Prx antibodies and thereafter with Protein A-gold conjugate. Methyl cellulose embedded sections were analysed with a transmission electron microscope.

## **5.3 Transcript analysis**

### ***5.3.1 Extraction of RNA (III and V)***

For RNA isolation, the cell pellets were stored at -70°C and tissue samples were incubated with RNAlater™ (Ambion) prior to storage in liquid nitrogen. The mRNAs of the cultured cells were extracted with the QuickPrep Micro mRNA Purification Kit (Amersham Pharmacia). Alternatively total RNA of cultured cells or human tissues was purified by Rneasy Mini Kit (Qiagen).

### ***5.3.2 Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) (III and V)***

The RT-PCR primers were designed to be cDNA specific and to contain at least one predicted intron sequence in order to avoid contamination of genomic DNA. Competitive

RT-PCR controls for Prxs were prepared by PCR using recombinant primers, which caused a 50-100 bp deletion into the product leaving the RT-PCR primer binding sites intact. These products were subcloned into pGem-3zf and amplified in *E. coli* XL1-blue strain. Plasmids were purified from the bacteria and RNA was produced by the Riboprobe *in vitro* transcription system (Promega) according to the manufacturer's instructions. Produced control RNA was used in the same RT-reaction as the mRNA under investigation. By preparing serial dilutions of the control RNA and comparing the amounts of PCR products from the control and studied mRNA it was possible to obtain an estimate of the amount of mRNA level in the sample.

#### **5.4 Assessment of proliferation and apoptosis (II)**

Proliferation of tumour cells was estimated immunohistochemically by staining with Ki-67 antibody. Apoptosis was detected by the ApopTag Kit (Oncor) that stains the 3'-ends of DNA fragments present in apoptotic cells.

#### **5.5 Computational and statistical analysis**

Alignment analyses were performed by BLAST programs available at [www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov) against nucleotide, expressed sequence tags of human (human-EST) or genomic nucleotide databases for designing proper primers for RT-PCR (Altschul *et al.* 1990). Genetic structure was predicted also to help primer design by comparing genomic sequences with cDNAs (GeneFinder, URL [www.bcm.edu](http://www.bcm.edu)). Promoter prediction and computational analysis was done by using the TFFACTOR, TFSITE and Eucaryotic Promoter Database (URL [www.embl-heidelberg.de](http://www.embl-heidelberg.de)) to help in the Prx regulation studies. Statistical analysis was performed with SPSS 10.0 or 11.5 for Windows (Chicago, IL, USA). Data was analysed using ANOVA and *post hoc* comparison (continuous data) or using Fisher's exact test (categorical data). Kaplan-Meier curves were used for survival studies and log-rank, Breslow and Tarone-Ware tests were used to test the statistical significance. Generally, probability values below 0.05 were considered statistically significant. The immunohistochemical evaluations of two pathologists were compared using Cohen's  $\kappa$  statistics to ensure good agreement.



## 6 Results

### 6.1 Peroxiredoxins in healthy human lung (I, II, III and IV)

All six Prxs were clearly detectable in homogenates of apparently normal lung by Western analysis and by RT-PCR. Immunohistochemical staining revealed the expression to be cell-specific according to table 3. Prxs I and III had a similar cell specific expression, that was highest in bronchial epithelial cells and alveolar macrophages, but lower expression could be detected in alveolar epithelium and vascular endothelium. Prx II was seen in epithelial cells and macrophages. Prx IV was expressed in bronchial epithelium and alveolar macrophages. Prxs V and VI were located in epithelium and a lesser extent in macrophages.

*Table 3. Cell-specific expression of Prxs in normal human lung.*

Cell type	Prx I	Prx II	Prx III	Prx IV	Prx V	Prx VI
Bronchial epithelium	Moderate	Low	High	Low	High	High
Endothelium	Low	No	Low	No	No	Low
Alveolar epithelium	Low	Low	Moderate	No	High	High
Alveolar macrophages	Moderate	Low	High	Low	Moderate	Moderate

Immunohistochemistry and immunoelectron microscopy revealed that the Prxs had different subcellular locations in the manner shown in figure 6. Even though Prxs can be detected in several compartments of the cell, their nuclear location can be seen only occasionally and not for example in cultured A549 cells.

### 6.2 Peroxiredoxins in pulmonary sarcoidosis (I)

The expression pattern of Prxs in parenchymal tissue and BAL fluid cells of pulmonary sarcoidosis was very similar to that seen in normal lung, but there was high expression of

Prxs I and III in granulomas detected by immunohistochemistry (table 4). Also Prxs IV, V and VI were detected in granulomas but less intensively.




Fig. 6. Subcellular locations of Prxs in cultured human lung cells.

### 6.3 Peroxiredoxins in malignant mesothelioma and lung carcinomas (II and III)

All of the Prxs except Prx IV were highly expressed in malignant mesothelioma, and their expressions were conspicuously higher than in normal pleura (table 4). In adenocarcinoma and squamous cell carcinoma Prxs I, II and IV were highly expressed compared to normal lung as reviewed in table 4. Additionally Prx VI was elevated in adenocarcinoma but not in squamous cell carcinoma. In particular high Prx IV expression was seen in adenocarcinoma and Prx VI expression was associated with high grade squamous cell carcinoma.

## 6.4 Peroxiredoxins, thioredoxin and thioredoxin reductase in smoker's lung and in chronic obstructive pulmonary disorder (IV)

Prxs were studied from lung homogenates of non-smokers, smokers and smokers with COPD. Since Prx VI is highly expressed in human lung and its role there is significant, Prxs V and VI were selected for more detailed analysis by immunohistochemistry. Trx and TrxR were also analysed in these cases.

Trx was significantly increased in the smokers' lung bronchial epithelium but other effects of smoking or COPD were quite small. Some increase in the expression of Prxs V and VI was seen in alveolar macrophages. A summary of Prx expression in the studied lung diseases is shown in table 4.


*Table 4. Expression of peroxiredoxins in various disorders of the lung or pleura compared to apparently normal tissue*

Prx	Pulmonary sarcoidosis, granulomas	COPD	Adeno-carcinoma, lung	Squamous cell carcinoma, lung	Pleural mesothelioma
I	Highly expressed	No alterations in homogenates	Increased	Increased	Increased
II	Not expressed	No alterations in homogenates	Increased	Increased	Increased
III	Highly expressed	No alterations in homogenates	No clear alterations	No clear alterations	Increased
IV	Highly expressed	No alterations in homogenates	Increased	Increased	No clear alterations
V	Highly expressed	Mild induction in macrophages	No clear alterations	No clear alterations	Increased
VI	Highly expressed	Mild induction in macrophages	Increased	No clear alterations	Increased

## 6.5 Peroxiredoxins in cultured cells (I, II, IV and V)

All Prxs were expressed very similarly in both non-malignant bronchial Beas 2B cells and in malignant A549 cells, except that Prx II was almost totally missing from A549

cells as could be seen both by RT-PCR and Western analysis. Prx expression was also very constant in both of these cell lines and could be induced only by the oxidative stress generated by H<sub>2</sub>O<sub>2</sub> exposure but not by agents like TNF $\alpha$ , TGF $\beta$ , BSO, cisplatin or menadione. Western analysis was performed generally 2, 4 or 6, 24, 48 and 72 hours after exposure. Quantitative RT-PCR was performed 30 min, 1, 4 or 24 hours after exposure but no alterations were seen. Also the catalytic cycle of Prxs was affected only by H<sub>2</sub>O<sub>2</sub>. Serum depletion/addition was tested, but also in these experiments the alterations were rather minor. A representative of oxidation state analysis is shown in figure 7. Oxidation state analysis was performed also from tissue samples of apparently normal lung tissue, adenocarcinoma, squamous cell carcinoma or COPD but there were no differences detected.



**Fig. 7.** Non-reducing SDS-PAGE analysis of Prx I (A) and III (B) 1, 24 or 48 hours after H<sub>2</sub>O<sub>2</sub> exposure (H) or unexposed control cells (C). Sites of dimeric (DI) and monomeric (MONO) forms are indicated by arrows.

## 6.6 Predicted gene structures and properties of peroxiredoxins

Before planning the competitive constructs for RT-PCR, the exon/intron boundaries were predicted by computational analysis from published human genome project sequences. Furthermore the predicted promoter sequences were analysed for transcription factor

binding sites. The amount of predicted exons is shown in table 5, where also the existence of the ARE sequence and selected putative transcription factor binding site are indicated.

*Table 5. Predicted properties of genomic sequences of human Prxs.*

Prx	Number of exons	ARE	Putative binding sites					
			NFκB	Ap1	Ap2	c-Myc	Sp1	Hif1
I	6	+	+	+	+		+	+
II	6	+	+	+	+		+	+
III	7	+				+	+	+
IV	7	+	+			+	+	+
V	6	+	+					+
VI	6	+	+					+

## 7 Discussion

The main goals of this project were first to study the expression of Prxs in human lung under normal physiological conditions and during selected lung disorders and secondly to study the role and regulation of Prxs by using cultured cells as model systems. The results showed minor alterations in Prx expression during non-malignant diseases but a remarkable increase during malignancies. Regulation of Prxs in cultured human lung cells was found to be TNF $\alpha$  and TGF $\beta$  independent, but slightly upregulated by high concentrations of H<sub>2</sub>O<sub>2</sub>. Furthermore, the issue about the role of Prxs in human lung, i.e. they have a protective or regulatory nature, remained ambiguous.

### 7.1 Peroxiredoxins in normal human lung (I, II, III, IV and V)

This was the first study of Prxs in human lung revealing their expression in normal lung and in various lung disorders. Prxs are abundant proteins existing in six different isoforms, but the reasons for their multiplicity and their interplay are mostly unclear. One explanation for the existence of six different Prxs was noted already in our preliminary studies, when different Prxs were observed in different cell types of the lung (I). Furthermore their subcellular compartmentalisation was clear. Prxs III and V were known to be present in organelles, Prx IV in extracellular space and Prx III had been previously detected in the nuclear fraction of cultured cells. Our results confirmed these localisations in lung cells and in addition our studies indicated that also other Prxs may not only have a nuclear location but they also may be occasionally concentrated in the nucleus. This phenomenon was mostly detected in the bronchial epithelium, but more rarely also in other areas of the lung. This raises the question about their role in the nucleus. Prx V has been reported to have DNA binding properties and possibly to regulate retroposon transcription (Kropotov *et al.* 1999), but no other direct connections of Prxs to DNA have been reported. It is also possible that their only purpose in the nucleus is to protect DNA from being exposed to ROS. This is supported by the fact that a strong nuclear location was observed in the bronchial epithelium, which experiences a very strong oxidative stress compared to other areas. On the other hand, also cultured cells are cultivated in an oxidant rich environment as compared to human tissues, but, as stated, no nuclear

location has been detected except for Prx III. These results suggest that there may be some sort of targeting machinery for Prxs, as their capability to passively translocate to the nucleus does not explain their concentration there and no traditional nuclear localisation signals are present in their sequences. The possible targeting force remained unsolved, is it  $H_2O_2$ , the general redox state or for example the cell cycle state. Trx is known to regulate directly the activity of certain transcription factors and therefore one cannot exclude a similar regulatory role for Prxs.

## 7.2 Peroxiredoxins in non-malignant diseases (I and IV)

Analysis of lung samples from patients with pulmonary sarcoidosis or COPD suggested that Prxs may have a role during inflammation. First all of the Prxs except Prx II were highly expressed in sarcoidosis granulomas, even though their expression elsewhere in the lung was very similar to normal lung. BAL cells mostly contain inflammatory cells and they seemed to have a slightly different Prx profiles in healthy controls and in sarcoidosis patients. Secondly we observed that macrophages were very heterogenous in how they expressed Prxs V and VI expressions, which may indicate different expression at different activation states of inflammatory cells or in different macrophage populations. As this induction was clear only in a subpopulation of macrophages, it is probable that this induction is caused more by intracellular signals than by for example the increased oxidative stress of present in the lungs of smokers.

Prxs V and VI were surprisingly constantly expressed in the epithelium of the airways of non-smokers, smokers and smokers with COPD. Similar results would be expected for the other Prxs as microarray studies performed on bronchial epithelium revealed only a minor induction of Prx IV in smoker's lung (Hackett *et al.* 2003, Golpon *et al.* 2004). In contrast, a clear induction of Trx by smoking could be seen. Since Prxs are not induced by cigarette smoke, it is probable that they do not provide any extra defence against the elevated oxidative stress. This could indicate either that the role of Prxs is non-AOE-like or they could be one part of AOE machinery that does not respond to oxidative stress forcefully thus resulting in accumulation of  $H_2O_2$ . The lack of induction by cigarette smoke is in line with studies that show Prx upregulation immediately after birth in rat lung and also with the reports that Prx expression is high in normal lung at ambient oxygen tension.

## 7.3 Peroxiredoxins in malignant diseases (II and III)

Several Prxs were upregulated in both lung carcinomas and malignant mesothelioma as expected from previous reports of high expression of Prx I in some other human malignancies (Yanagawa *et al.* 1999, Yanagawa *et al.* 2000, Chang *et al.* 2001, Noh *et al.* 2001, Choi *et al.* 2002, Karihtala *et al.* 2003). Obviously the Prx expression pattern was different in different carcinoma subtypes such that Prxs III and V levels were high especially in pleural mesothelioma, Prx VI in pleural mesothelioma and adenocarcinoma but not in squamous cell carcinoma, Prx IV in adenocarcinoma and squamous cell

carcinoma but not in pleural mesothelioma. These results highlight the need for further studies to map their possible use in diagnostics, for example differentiating malignant pleural mesothelioma from metastatic carcinomas which have spread to pleura.

Prx I is a potent tumor suppressor, but it was highly expressed in lung carcinomas as well as in malignant pleural mesothelioma in a manner similar to that occurring in several other carcinomas. This apparent disagreement is explained by the different phases of tumor initiation and progression. At the very early stages, the lack of Prx I makes cells more susceptible to oxidative damage and thus increases the accumulation of mutations ultimately leading to malignant transformation. It is not known whether decrease of Prx I occurs in human tissues and is one of the factors leading to cancer, but it would be interesting to follow its behaviour as cells are transformed. Once the cell has been transformed, Prx I expression would however be favourable for cancer progression as it would protect cells from apoptosis, which explains why several tumors contain high levels of this enzyme. In some COPD patients there were dysplastic areas in their bronchi and in these regions, Prx V and VI expressions were lower than in the surrounding epithelium, but reliable results would require analysis of more samples.

Prxs II and VI, the other cytosolic Prxs, were generally induced in malignancies, except for Prx VI in squamous cell carcinoma which showed no difference from normal lung. These differences between various carcinoma types could be simply explained by the different origins of these cells. A more elaborate explanation would be the different proliferation rate of these cells or some other yet unidentified system affecting Prx expression. Ultimately the factors leading to high Prx expression in malignant cells remained unclear. It is possible that elevated metabolic activity, increased proliferation or improved ability of the cancer cell to protect itself against apoptosis would be directly or indirectly affecting the Prx expression.

## 7.4 Oxidation state of peroxiredoxins (IV and V)

In tissues, Prxs I-IV are present mostly as dimers, but in cultured cells a higher proportion seemed to exist as a monomer (IV and V). During the normal catalytical cycle, Prxs fluctuate between monomeric and dimeric forms, but when the cells were treated with more than 50  $\mu\text{M}$   $\text{H}_2\text{O}_2$ , the balance was disturbed so that the proportion of the monomeric form increased. This was presumably because of overoxidation, which transiently inactivates Prxs. The importance of this type of regulation in human tissues remains unclear. However, recently characterized sulfiredoxin, the rescuer of overoxidised forms of 2-Cys Prxs, poses several questions and explanations. Sulfiredoxin is not expressed in all cell types. Thus in some tissues, Prx overoxidation may be irreversible and thus allow  $\text{H}_2\text{O}_2$  accumulation and its long-term usage as a second messenger. In other tissues, sulfiredoxin is expressed at high levels and thus allows efficient  $\text{H}_2\text{O}_2$  removal constantly offering good protection against oxidative stress. Sulfiredoxin catalyses the reduction relatively slowly in cells, which could even give time for the initiation of apoptotic signaling after the  $\text{H}_2\text{O}_2$  burst.

Even though overexpression studies on cultured cells have indicated that Prxs break down  $\text{H}_2\text{O}_2$  generated after  $\text{TNF}\alpha$  exposure (Kang *et al.* 1998b), we did not observe any



alteration in Prxs I-IV dimer/monomer ratio after  $\text{TNF}\alpha$ ,  $\text{TGF}\beta$  or BSO treatments. It is however possible that they degrade  $\text{H}_2\text{O}_2$ , but do so in a way that their catalytic cycle is not affected. On the other hand, the differences of the redox state between cultured cells and tissue biopsies suggests that cultured cells grown under conventional conditions may not represent a good model for this kind of study, since under normal cell culture conditions, a high proportion of Prxs might be inactivated.

## 7.5 Regulation of peroxiredoxin expression (V)

One important aim of this study was to identify factors regulating Prx expression. However, the growth factors, cytokines or other treatments that regulate the traditional AOE had no effect on Prx expression in cultured cells. The depletion of GSH by BSO or serum starvation of the cells also had surprisingly small effects on Prx expression, even though serum has been reported to induce Prx I expression in murine cells (Ishii *et al.* 1993, Prosperi *et al.* 1998).

Computational analysis of the predicted promoter areas of Prxs showed some putative binding sites for Ap1,  $\text{NF}\kappa\text{B}$ , c-myc and Hif1. These predictions do not however actually determine, whether these sites are functional or not. Preliminary attempts were made for Ap1 and  $\text{NF}\kappa\text{B}$  depletion by antisense techniques, but no effects on Prx expression were seen. Also the lack of induction by  $\text{TNF}\alpha$  would suggest only minor  $\text{NF}\kappa\text{B}$  mediated regulation. In mouse, c-myc regulates Prx III expression and as there are several putative binding sites of c-myc in the predicted Prx promoters, c-myc seems likely to be one of the transcription factors involved. Additionally Nrf2 regulated induction in inflammatory cells may be the most important mechanism also in non-malignant human lung (Ishii *et al.* 2000). Very impressive Prx expression was seen in malignant tissue samples, but the precise upregulator triggering this process remained unsolved. It is probably attributable to several different factors including a mixture of growth factors and other regulators leading to the high proliferation.

## 7.6 Methodological aspects (I, II, III, IV and V)

Human lung contains dozens of different cell types, which makes it a very challenging target for research. The best way to study the protein expression of the lung is obviously immunohistochemistry, which was the most important method also used in these studies. Samples of lung tissue homogenates or BAL fluid cells can be very heterogeneous, for example the amount of macrophages may vary greatly not only between individuals but also in various areas of the same lung. Therefore it is not surprising that Western analysis of homogenates did not invariably correlate with the more detailed immunohistochemical findings (III and IV). In addition, it must be kept in mind that Prx IV is extracellular and Prxs III and V are organellar, which make these enzymes difficult to measure by immunohistochemistry as a proportion of extracellular proteins may escape during sample preparation and granular staining of organelles is difficult to evaluate. It is most likely that especially Prx IV is underestimated by immunohistochemistry. Therefore

further studies were conducted using several methodologies with the same tissue specimens. Immunoelectron microscopy provides more specific information about localisation, but as also here, it can be performed only in a very limited area and thus reveals expression only in a few cells. One major disadvantage of immunohistochemistry is the method used for evaluation of staining, since the assessment of positivity is very subjective, and requires several independent assessments of the same sample. Thus it is both time-consuming and not particularly accurate. However, as the samples are very heterogeneous with all different cell types, a great deal of information may be lost if samples are evaluated only by means of positive area.

*In situ* hybridization was viewed as a good method for detecting expression at the transcriptional level in the lung. Therefore constructs for probe production were subcloned for different *Prxs* for further studies. A quantitative RT-PCR system was set up for these studies and they provided information about transcript levels in cultured cells but also in few cases in lung homogenates. In particular lung homogenate studies by RT-PCR and Western analysis suggested that some *Prxs* are strongly regulated at the translational level (III), therefore *in situ* hybridization might give interesting results to compare with immunohistochemistry. Especially *Prx V* expression was clearly different in tissue samples by RT-PCR and Western analysis (III), which pointed to strong translational regulation or that perhaps there are two distinct transcripts in human cells similarly to the situation in mice, which have short and long forms. This was not tested by Northern blotting, but attempts were made to amplify two forms from human lung cDNA library by RT-PCR, but only one size transcript was amplified. This does not exclude the existence of longer transcript, especially as PCR favors shorter products.

*Prxs* are regulated also at the posttranslational level by phosphorylation and oxidation. There are some antibodies available for specifically these modified forms, but at least the antibody against phosphorylated *Prx I* did not work properly in immunohistochemistry nor Western, probably due to low levels of this protein form. Activity measurements would provide information about *Prx* modifications as phosphorylated and overoxidised forms are inactive, but this is difficult from tissue samples, as the correct use of this method would need sample fractionation, which is limited by small size of biopsy samples and this procedure itself might alter the protein conformation/activity. Therefore Western analysis was performed after non-reducing electrophoresis, which shows monomeric and dimeric forms of *Prxs I-IV* in different positions. This method does not directly reveal *Prx* activity, but reflects more disturbances in the catalytical cycle and in its simplicity provides a useful alternative to 2-dimensional electrophoresis, which separates proteins both based on their size and isoelectric point. On the other hand, the monomeric form may contain functional thiol or sulphenic acid groups, but there can be also non-functional sulphonic or sulphinic acid. The monomeric form could also, in theory, represent the unfolded form of *Prx*, as in addition to transcriptional responses, the stress experienced by the cell not only reduces translation but also reduces protein folding leading to the accumulation of unfolded proteins in endoplasmic reticulum. Also alterations in the redox state may occur during sample preparation and this factor must be carefully considered especially when using tissue samples.

There are several under- and overexpression studies with *Prx* but no systematic studies on their regulation in intact cells. Therefore, cultured cells were used as a model for *Prx* expression. They were highly expressed in cultured cells, at about the same magnitude as

in carcinoma tissue but this expression was hard to manipulate with any tested agent. Possibly Prxs are up-regulated already in conventional cell culturing conditions, i.e. cells under high oxygen pressure and with several growth factors or serum added to the medium. A high basal level of expression may make it impossible to detect significant induction even by factors that may have a crucial role *in vivo*. These results do not rule out the possibility of a regulatory role for TNF $\alpha$ , TGF $\beta$  or other factors *in vivo*. In future studies it should be possible to reduce Prx amount in the cells via antisense technology and this may be one way to obtain information about their expression and especially their importance in cultured lung cells.

In addition to the small sample size also number of available samples was a limiting factor. In common diseases like COPD, the samples were easier to obtain, but for example it proved difficult to acquire a suitable amount of samples from patients with usual interstitial pneumonia even though our preliminary results were very interesting. In particular, the number of healthy controls was very small in all of these studies and they mostly contained individuals with minor respiratory symptoms. There are also other problems in obtaining lung tissue or BAL samples, especially if one wishes to study the redox system. Anaesthetic agents and elevated oxygen pressure during operation are procedures that can affect the redox state and the expression of AOE's.

## 8 Conclusions

1. All the members of Prx family are expressed in human lung but they are expressed in a cell-specific manner. The expression is generally highest in the epithelium and in inflammatory cells.
2. Several Prxs are highly expressed in granulomas of sarcoidosis, while the expression in non-granulomatous inflammatory areas is not affected.
3. Several Prxs are highly expressed in malignant mesothelioma, adenocarcinoma and squamous cell carcinoma. The expression pattern differs between different carcinoma subtypes.
4. The Prx expression pattern in the lungs of smokers or COPD patients is rather similar to that found in healthy non-smokers. The only difference was seen in alveolar macrophages, which contained more Prx V and VI positivity in COPD patients' lung than in healthy non-smokers' lung. However, Trx expression was elevated in bronchial epithelium of smoker's lung compared to healthy bronchial tissue from non-smokers.
5. It was difficult to modify Prx levels in cultured cells. None of the tested growth factors or cytokines affected the transcription or translation, only very strong oxidative stress created by high concentrations of H<sub>2</sub>O<sub>2</sub> increased the expression. Strong oxidative stress also affected the oxidation state of 2-Cys Prxs, presumably inactivating them.

## 9 References

- Altschul SF, Gish W, Miller W, Myers EW & Lipman DJ (1990) Basic local alignment search tool. *J Mol Biol* 215: 403-410.
- Ammendola R, Mesuraca M, Russo T & Cimino F (1994) The DNA-binding efficiency of Sp1 is affected by redox changes. *Eur J Biochem* 225: 483-489.
- Anderson MT, Staal FJ, Gitler C, Herzenberg LA & Herzenberg LA (1994) Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. *Proc Natl Acad Sci U S A* 91: 11527-11531.
- Arnaiz SL, Travacio M, Llesuy S & Boveris A (1995) Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. *Biochim Biophys Acta* 1272: 175-180.
- Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB & Rhee SG (1997) Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. *J Biol Chem* 272: 217-221.
- Baea G-U, Kimb YK, Kwona H-K, Parka JW, Leea EK, Paeka SJ, Choic WS, Jungd ID, Leed HY, Choa E-J, Leea HW & Hana J-W (2004) Hydrogen peroxide mediates Rac1 activation of S6K1. *Exp Cell Res* 300: 476-484.
- Baier M & Dietz KJ (1996) Primary structure and expression of plant homologues of animal and fungal thioredoxin-dependent peroxide reductases and bacterial alkyl hydroperoxide reductases. *Plant Mol Biol* 31: 553-564.
- Baier M & Dietz KJ (1999) Protective function of chloroplast 2-cysteine peroxiredoxin in photosynthesis. Evidence from transgenic Arabidopsis. *Plant Physiol* 119: 1407-1414.
- Balcewicz-Sablinska MK, Wollman EE, Gorti R & Silberstein DS (1991) Human eosinophil cytotoxicity-enhancing factor. II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor. *J Immunol* 147: 2170-2174.
- Banmeyer I, Marchand C, Verhaeghe C, Vucic B, Rees JF & Knoops B (2004) Overexpression of human peroxiredoxin 5 in subcellular compartments of Chinese hamster ovary cells: effects on cytotoxicity and DNA damage caused by peroxides. *Free Radic Biol Med* 36: 65-77.
- Behrend L, Henderson G & Zwacka RM (2003) Reactive oxygen species in oncogenic transformation. *Biochem Soc Trans* 31: 1441-1444.
- Berggren MI, Husbeck B, Samulitis B, Baker AF, Gallegos A & Powis G (2001) Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in

- enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. *Arch Biochem Biophys* 392: 103-109.
- Biteau B, Labarre J & Toledano MB (2003) ATP-dependent reduction of cysteine-sulphinic acid by *S. cerevisiae* sulphiredoxin. *Nature* 425: 980-984.
- Boveris A & Chance B (1973) The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. *Biochem J* 134: 707-716.
- Bowie AG, Moynagh PN & O'Neill LA (1997) Lipid peroxidation is involved in the activation of NF-kappaB by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304. Lack of involvement of H<sub>2</sub>O<sub>2</sub> in NF-kappaB activation by either cytokine in both primary and transformed endothelial cells. *J Biol Chem* 272: 25941-25950.
- Brigelius-Flohe R (1999) Tissue-specific functions of individual glutathione peroxidases. *Free Radic Biol Med* 27: 951-965.
- Burdon RH, Alliangana D & Gill V (1995) Hydrogen peroxide and the proliferation of BHK-21 cells. *Free Radic Res* 23: 471-486.
- Calhoun WJ, Salisbury SM, Chosy LW & Busse WW (1988) Increased alveolar macrophage chemiluminescence and airspace cell superoxide production in active pulmonary sarcoidosis. *J Lab Clin Med* 112: 147-156.
- Cantin AM, Fells GA, Hubbard RC & Crystal RG (1990) Antioxidant macromolecules in the epithelial lining fluid of the normal human lower respiratory tract. *J Clin Invest* 86: 962-971.
- Cantin AM, North SL, Hubbard RC & Crystal RG (1987) Normal alveolar epithelial lining fluid contains high levels of glutathione. *J Appl Physiol* 63: 152-157.
- Carlsson LM, Jonsson J, Edlund T & Marklund SL (1995) Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia. *Proc Natl Acad Sci U S A* 92: 6264-6268.
- Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A & Ghezzi P (2002) Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. *Proc Natl Acad Sci U S A* 99: 9745-9749.
- Cha MK, Yun CH & Kim IH (2000) Interaction of human thiol-specific antioxidant protein 1 with erythrocyte plasma membrane. *Biochemistry* 39: 6944-6950.
- Chae HZ, Chung SJ & Rhee SG (1994) Thioredoxin-dependent peroxide reductase from yeast. *J Biol Chem* 269: 27670-27678.
- Chae HZ, Kim IH, Kim K & Rhee SG (1993) Cloning, sequencing, and mutation of thiol-specific antioxidant gene of *Saccharomyces cerevisiae*. *J Biol Chem* 268: 16815-16821.
- Chae HZ, Robison K, Poole LB, Church G, Storz G & Rhee SG (1994b) Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. *Proc Natl Acad Sci U S A* 91: 7017-7021.
- Chandel NS & Schumacker PT (2000) Cellular oxygen sensing by mitochondria: old questions, new insight. *J Appl Physiol* 88: 1880-1889.
- Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH & Yoo YJ (2001) Augmented expression of peroxiredoxin I in lung cancer. *Biochem Biophys Res Commun* 289: 507-512.
- Chang TS, Cho CS, Park S, Yu S, Kang SW & Rhee SG (2004a) Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. *J Biol Chem* 279: 41975-41984.
- Chang TS, Jeong W, Choi SY, Yu S, Kang SW & Rhee SG (2002) Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. *J Biol Chem* 277: 25370-25376.

- Chang TS, Jeong W, Woo HA, Lee SM, Park S & Rhee SG (2004b) Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. *J Biol Chem* 279: 50994-51001.
- Chena KC-W, Zhou Y, Xing K, Krysanc K, Loua MF (2004) Platelet derived growth factor (PDGF)-induced reactive oxygen species in the lens epithelial cells: the redox signaling. *Exp Eye Res* 78: 1057-1067.
- Chiu C, Maddock DA, Zhang Q, Souza KP, Townsend AR & Wan Y (2001) TGF-beta-induced p38 activation is mediated by Rac1-regulated generation of reactive oxygen species in cultured human keratinocytes. *Int J Mol Med* 8: 251-255.
- Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR & Kim JR (2002) Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. *Anticancer Res* 22: 3331-3335.
- Chung YM, Yoo YD, Park JK, Kim YT & Kim HJ (2001) Increased expression of peroxiredoxin II confers resistance to cisplatin. *Anticancer Res* 21: 1129-1133.
- Cooper CE, Patel RP, Brookes PS & Darley-Usm VM (2002) Nanotransducers in cellular redox signaling: modification of thiols by reactive oxygen and nitrogen species. *Trends Biochem Sci* 27: 489-492.
- Crack PJ, Taylor JM, de Haan JB, Kola I, Hertzog P & Iannello RC (2003) Glutathione peroxidase-1 contributes to the neuroprotection seen in the superoxide dismutase-1 transgenic mouse in response to ischemia/reperfusion injury. *J Cereb Blood Flow Metab* 23: 19-22.
- Das KC, Pahl PM, Guo XL & White CW (2001) Induction of peroxiredoxin gene expression by oxygen in lungs of newborn primates. *Am J Respir Cell Mol Biol* 25: 226-232.
- Dubuisson M, Vander SD, Clippe A, Etienne F, Nauser T, Kissner R, Koppenol WH, Rees JF & Knoop B (2004) Human peroxiredoxin 5 is a peroxynitrite reductase. *FEBS Lett* 571: 161-165.
- Fisher AB, Dodia C, Manevich Y, Chen JW & Feinstein SI (1999) Phospholipid hydroperoxides are substrates for non-selenium glutathione peroxidase. *J Biol Chem* 274: 21326-21334.
- Flentjar NJ, Crack PJ, Boyd R, Malin M, de Haan JB, Hertzog P, Kola I & Iannello R (2002) Mice lacking glutathione peroxidase-1 activity show increased TUNEL staining and an accelerated inflammatory response in brain following a cold-induced injury. *Exp Neurol* 177: 9-20.
- Forman HJ & Azzi A (1997) On the virtual existence of superoxide anions in mitochondria: thoughts regarding its role in pathophysiology. *FASEB J* 11: 374-375.
- Fratelli M, Demol H, Puype M, Casagrande S, Eberini I, Salmona M, Bonetto V, Mengozzi M, Duffieux F, Miclet E, Bachi A, Vandekerckhove J, Gianazza E & Ghezzi P (2002) Identification by redox proteomics of glutathionylated proteins in oxidatively stressed human T lymphocytes. *Proc Natl Acad Sci U S A* 99: 3505-3510.
- Freedman RB, Hirst TR & Tuite MF (1994) Protein disulphide isomerase: building bridges in protein folding. *Trends Biochem Sci* 19: 331-336.
- Gasdaska PY, Oblong JE, Cotgreave IA & Powis G (1994) The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. *Biochim Biophys Acta* 1218: 292-296.
- Gerdes J, Lemke H, Baisch H, Wacker HW, Schwab U & Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J Immunol* 133: 1710-1715.
- Gilks CB, Price K, Wright JL & Churg A (1998) Antioxidant gene expression in rat lung after exposure to cigarette smoke. *Am J Pathol* 152: 269-278.

- Golpon HA, Coldren CD, Zamora MR, Cosgrove GP, Moore MD, Tuder RM, Geraci MW & Voelkel NF (2004) Emphysema lung tissue gene expression profiling. *Am J Respir Cell Mol Biol* 31: 595-600.
- Green DR & Reed JC (1998) Mitochondria and apoptosis. *Science* 281: 1309-1312.
- Greenberg JT & Demple B (1988) Overproduction of peroxide-scavenging enzymes in *Escherichia coli* suppresses spontaneous mutagenesis and sensitivity to redox-cycling agents in oxyR-mutants. *EMBO J* 7: 2611-2617.
- Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A & Powis G (2000) Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. *Hum Pathol* 31: 475-481.
- Hackett NR, Heguy A, Harvey BG, O'Connor TP, Luettich K, Flieder DB, Kaplan R & Crystal RG (2003) Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. *Am J Respir Cell Mol Biol* 29: 331-343.
- Haridas V, Ni J, Meager A, Su J, Yu GL, Zhai Y, Kyaw H, Akama KT, Hu J, Van Eldik LJ & Aggarwal BB (1998) TRANK, a novel cytokine that activates NF-kappa B and c-Jun N-terminal kinase. *J Immunol* 161: 1-6.
- Harris JR & Naeem I (1981) Further studies on the characterization of cylindrin and torin, two extrinsic proteins of the erythrocyte membrane. *Biochim Biophys Acta* 670: 285-290.
- Harris JR, Schroder E, Isupov MN, Scheffler D, Kristensen P, Littlechild JA, Vagin AA & Meissner U (2001) Comparison of the decameric structure of peroxiredoxin-II by transmission electron microscopy and X-ray crystallography. *Biochim Biophys Acta* 1547: 221-234.
- Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, Yasuda H, Karin M & Kikugawa K (2003) Evidence that reactive oxygen species do not mediate NF-kappaB activation. *EMBO J* 22: 3356-3366.
- Hayashi T, Ueno Y & Okamoto T (1993) Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. *J Biol Chem* 268: 11380-11388.
- Heck DE, Vetrano AM, Mariano TM & Laskin JD (2003) UVB light stimulates production of reactive oxygen species: unexpected role for catalase. *J Biol Chem* 278: 22432-22436.
- Hensley K & Floyd RA (2002) Reactive oxygen species and protein oxidation in aging: a look back, a look ahead. *Arch Biochem Biophys* 397: 377-383.
- Hillar A, Peters B, Pauls R, Loboda A, Zhang H, Mauk AG & Loewen PC (2000) Modulation of the activities of catalase-peroxidase HPI of *Escherichia coli* by site-directed mutagenesis. *Biochemistry* 39: 5868-5875.
- Hirose K, Longo DL, Oppenheim JJ & Matsushima K (1993) Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. *FASEB J* 7: 361-368.
- Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K & Yodoi J (1997) AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. *Proc Natl Acad Sci U S A* 94: 3633-3638.
- Ho YS, Magnenat JL, Bronson RT, Cao J, Gargano M, Sugawara M & Funk CD (1997) Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. *J Biol Chem* 272: 16644-16651.
- Holmes B, Page AR & Good RA (1967) Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function. *J Clin Invest* 46: 1422-1432.
- Holmgren A (1989) Thioredoxin and glutaredoxin systems. *J Biol Chem* 264: 13963-13966.



- Ichinose M, Sugiura H, Yamagata S, Koarai A & Shirato K (2000) Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. *Am J Respir Crit Care Med* 162: 701-706.
- Imlay JA & Fridovich I (1991) Assay of metabolic superoxide production in *Escherichia coli*. *J Biol Chem* 266: 6957-6965.
- Immenschuh S, Baumgart-Vogt E, Tan M, Iwahara S, Ramadori G & Fahimi HD (2003) Differential cellular and subcellular localization of heme-binding protein 23/peroxiredoxin I and heme oxygenase-1 in rat liver. *J Histochem Cytochem* 51: 1621-1631.
- Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S & Yamamoto M (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. *J Biol Chem* 275: 16023-16029.
- Ishii T, Yamada M, Sato H, Matsue M, Taketani S, Nakayama K, Sugita Y & Bannai S (1993) Cloning and characterization of a 23-kDa stress-induced mouse peritoneal macrophage protein. *J Biol Chem* 268: 18633-18636.
- Ivery MT (2000) Immunophilins: switched on protein binding domains? *Med Res Rev* 20: 452-484.
- Iwahara S, Satoh H, Song DX, Webb J, Burlingame AL, Nagae Y & Muller-Eberhard U (1995) Purification, characterization, and cloning of a heme-binding protein (23 kDa) in rat liver cytosol. *Biochemistry* 34: 13398-13406.
- Jacobson FS, Morgan RW, Christman MF & Ames BN (1989) An alkyl hydroperoxide reductase from *Salmonella typhimurium* involved in the defense of DNA against oxidative damage. Purification and properties. *J Biol Chem* 264: 1488-1496.
- Jackson JH, Schraufstatter IU, Hyslop PA, Vosbeck K, Sauerheber R, Weitzman SA & Cochrane CG (1987) Role of oxidants in DNA damage. Hydroxyl radical mediates the synergistic DNA damaging effects of asbestos and cigarette smoke. *J Clin Invest* 80: 1090-1095.
- Jaiswal AK (1994) Antioxidant response element. *Biochem Pharmacol* 48: 439-444.
- Janssen-Heininger YM, Macara I & Mossman BT (1999) Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-kappaB: requirement of Ras/mitogen-activated protein kinases in the activation of NF-kappaB by oxidants. *Am J Respir Cell Mol Biol* 20: 942-952.
- Jaschke A, Mi H & Tropschug M (1998) Human T cell cyclophilin18 binds to thiol-specific antioxidant protein Aop1 and stimulates its activity. *J Mol Biol* 277: 763-769.
- Jeong JS, Kwon SJ, Kang SW, Rhee SG & Kim K (1999) Purification and characterization of a second type thioredoxin peroxidase (type II TPx) from *Saccharomyces cerevisiae*. *Biochemistry* 38: 776-783.
- Jin DY, Chae HZ, Rhee SG & Jeang KT (1997) Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. *J Biol Chem* 272: 30952-30961.
- Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, Lambeth JD & Berk BC (2000) Cyclophilin A is a secreted growth factor induced by oxidative stress. *Circ Res* 87: 789-796.
- Jones PL, Kucera G, Gordon H & Boss JM (1995) Cloning and characterization of the murine manganous superoxide dismutase-encoding gene. *Gene* 153: 155-161.
- Järvinen K, Soini Y, Kahlos K & Kinnula VL (2002) Overexpression of gamma-glutamylcysteine synthetase in human malignant mesothelioma. *Hum Pathol* 33: 748-755.
- Kahlos K, Anttila S, Asikainen T, Kinnula K, Raivio KO, Mattson K, Linnainmaa K & Kinnula VL (1998) Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. *Am J Respir Cell Mol Biol* 18: 570-580.

- Kahlos K, Soini Y, Säily M, Koistinen P, Kakko S, Pääkkö P, Holmgren A & Kinnula VL (2001a) Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma *Int J Cancer* 95: 198-204.
- Kahlos K, Soini Y, Sormunen R, Kaarteenaho-Wiik R, Pääkkö P, Linnainmaa K & Kinnula VL (2001b) Expression and prognostic significance of catalase in malignant mesothelioma. *Cancer* 91: 1349-1357.
- Kamp DW, Graceffa P, Pryor WA & Weitzman SA (1992) The role of free radicals in asbestos-induced diseases. *Free Radic Biol Med* 12: 293-315.
- Kang SW, Baines IC & Rhee SG (1998a) Characterization of a mammalian peroxiredoxin that contains one conserved cysteine. *J Biol Chem* 273: 6303-6311.
- Kang SW, Chae HZ, Seo MS, Kim K, Baines IC & Rhee SG (1998b) Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. *J Biol Chem* 273: 6297-6302.
- Kang SW, Chang TS, Lee TH, Kim ES, Yu DY & Rhee SG (2004) Cytosolic peroxiredoxin attenuates the activation of Jnk and p38 but potentiates that of Erk in Hela cells stimulated with tumor necrosis factor-alpha. *J Biol Chem* 279: 2535-2543.
- Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL & Soini Y (2003) Peroxiredoxins in breast carcinoma. *Clin Cancer Res* 9: 3418-3424.
- Kasai H, Okada Y, Nishimura S, Rao MS & Reddy JK (1989) Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator. *Cancer Res* 49: 2603-2605.
- Kawai S, Takeshita S, Okazaki M, Kikuno R, Kudo A & Amann E (1994) Cloning and characterization of OSF-3, a new member of the MER5 family, expressed in mouse osteoblastic cells. *J Biochem (Tokyo)* 115: 641-643.
- Kelner MJ & Montoya MA (1998) Structural organization of the human selenium-dependent phospholipid hydroperoxide glutathione peroxidase gene (GPX4): chromosomal localization to 19p13.3. *Biochem Biophys Res Commun* 249: 53-55.
- Kim H, Lee TH, Park ES, Suh JM, Park SJ, Chung HK, Kwon OY, Kim YK, Ro HK & Shong M (2000) Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. *J Biol Chem* 275: 18266-18270.
- Kim HS, Kang SW, Rhee SG & Clerch LB (2001a) Rat lung peroxiredoxins I and II are differentially regulated during development and by hyperoxia. *Am J Physiol Lung Cell Mol Physiol* 280: L1212-L1217.
- Kim HS, Manevich Y, Feinstein SI, Pak JH, Ho YS & Fisher AB (2003) Induction of 1-cys peroxiredoxin expression by oxidative stress in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 285: L363-L369.
- Kim HS, Pak JH, Gonzales LW, Feinstein SI & Fisher AB (2002) Regulation of 1-cys peroxiredoxin expression in lung epithelial cells. *Am J Respir Cell Mol Biol* 27: 227-233.
- Kim IH, Kim K & Rhee SG (1989) Induction of an antioxidant protein of *Saccharomyces cerevisiae* by O<sub>2</sub>, Fe<sup>3+</sup>, or 2-mercaptoethanol. *Proc Natl Acad Sci U S A* 86: 6018-6022.
- Kim K, Kim IH, Lee KY, Rhee SG & Stadtman ER (1988) The isolation and purification of a specific "protector" protein which inhibits enzyme inactivation by a thiol/Fe(III)/O<sub>2</sub> mixed-function oxidation system. *J Biol Chem* 263: 4704-4711.
- Kim SH, Fountoulakis M, Cairns N & Lubec G (2001b) Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. *J Neural Transm Suppl*: 223-235.

- Kim TS, Dodia C, Chen X, Hennigan BB, Jain M, Feinstein SI & Fisher AB (1998) Cloning and expression of rat lung acidic Ca<sup>2+</sup>-independent PLA2 and its organ distribution. *Am J Physiol* 274: L750-L761.
- Kim TS, Sundaresh CS, Feinstein SI, Dodia C, Skach WR, Jain MK, Nagase T, Seki N, Ishikawa K, Nomura N & Fisher AB (1997) Identification of a human cDNA clone for lysosomal type Ca<sup>2+</sup>-independent phospholipase A2 and properties of the expressed protein. *J Biol Chem* 272: 2542-2550.
- Kinnula VL & Crapo JD (2003) Superoxide dismutases in the lung and human lung diseases. *Am J Respir Crit Care Med* 167: 1600-1619.
- Kinnula VL & Crapo JD (2004) Superoxide dismutases in malignant cells and human tumors. *Free Radic Biol Med* 36: 718-744.
- Kinnula VL, Pääkkö P & Soini Y (2004) Antioxidant enzymes and redox regulating thiol proteins in malignancies of human lung. *FEBS Lett* 569: 1-6.
- Kirkman HN & Gaetani GF (1984) Catalase: a tetrameric enzyme with four tightly bound molecules of NADPH. *Proc Natl Acad Sci U S A* 81: 4343-4347.
- Knaapen AM, Borm PJ, Albrecht C & Schins RP (2004) Inhaled particles and lung cancer. Part A: Mechanisms. *Int J Cancer* 109: 799-809.
- Knoops B, Clippe A, Bogard C, Arsalane K, Wattiez R, Hermans C, Duconseille E, Falmagne P & Bernard A (1999) Cloning and characterization of AOEB166, a novel mammalian antioxidant enzyme of the peroxiredoxin family. *J Biol Chem* 274: 30451-30458.
- Kortemme T & Creighton TE (1995) Ionisation of cysteine residues at the termini of model alpha-helical peptides. Relevance to unusual thiol pK<sub>a</sub> values in proteins of the thioredoxin family. *J Mol Biol* 253: 799-812.
- Kropotov A, Sedova V, Ivanov V, Sazeeva N, Tomilin A, Krutilina R, Oei SL, Griesenbeck J, Buchlow G & Tomilin N (1999) A novel human DNA-binding protein with sequence similarity to a subfamily of redox proteins which is able to repress RNA-polymerase-III-driven transcription of the Alu-family retroposons in vitro. *Eur J Biochem* 260: 336-346.
- Kropotov AV, Grudinkin PS, Pleskach NM, Gavrilov BA, Tomilin NV & Zhivotovsky B (2004) Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks. *FEBS Lett* 572: 75-79.
- Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE & Lindahl T (1996) Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. *EMBO J* 15: 6662-6670.
- Lakari E, Pääkkö P & Kinnula VL (1998) Manganese superoxide dismutase, but not CuZn superoxide dismutase, is highly expressed in the granulomas of pulmonary sarcoidosis and extrinsic allergic alveolitis. *Am J Respir Crit Care Med* 158: 589-596.
- Lakari E, Pääkkö P, Pietarinen-Runtti P & Kinnula VL (2000) Manganese superoxide dismutase and catalase are coordinately expressed in the alveolar region in chronic interstitial pneumonias and granulomatous diseases of the lung. *Am J Respir Crit Care Med* 161: 615-621.
- Langen RC, Korn SH & Wouters EF (2003) ROS in the local and systemic pathogenesis of COPD. *Free Radic Biol Med* 35: 226-235.
- Lee J, Spector D, Godon C, Labarre J & Toledano MB (1999) A new antioxidant with alkyl hydroperoxide defense properties in yeast. *J Biol Chem* 274: 4537-4544.
- Lee SC, Chae HZ, Lee JE, Kwon BD, Lee JB, Won YH, Ahn KY & Kim YP (2000a) Peroxiredoxin is ubiquitously expressed in rat skin: isotype-specific expression in the epidermis and hair follicle. *J Invest Dermatol* 115: 1108-1114.

- Lee TH, Kim SJ, Kang SW, Lee KK, Rhee SG & Yu DY (2000b) Molecular cloning and characterization of the mouse peroxiredoxin V gene. *Biochem Biophys Res Commun* 270: 356-362.
- Lee TH, Kim SU, Yu SL, Kim SH, Park dS, Moon HB, Dho SH, Kwon KS, Kwon HJ, Han YH, Jeong S, Kang SW, Shin HS, Lee KK, Rhee SG & Yu DY (2003) Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. *Blood* 101: 5033-5038.
- Li B, Ishii T, Tan CP, Soh JW & Goff SP (2002a) Pathways of induction of peroxiredoxin I expression in osteoblasts: roles of p38 mitogen-activated protein kinase and protein kinase C. *J Biol Chem* 277: 12418-12422.
- Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ & Shah AM (2002b) Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. *Circ Res* 90: 143-150.
- Li WC, Wang GM, Wang RR & Spector A (1994) The redox active components H<sub>2</sub>O<sub>2</sub> and N-acetyl-L-cysteine regulate expression of c-jun and c-fos in lens systems. *Exp Eye Res* 59: 179-190.
- Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C & Chan PH (1995) Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. *Nat Genet* 11: 376-381.
- Lim YS, Cha MK, Kim HK & Kim IH (1994) The thiol-specific antioxidant protein from human brain: gene cloning and analysis of conserved cysteine regions. *Gene* 140: 279-284.
- Lindau-Shepard B, Shaffer JB & Del Vecchio PJ (1994) Overexpression of manganous superoxide dismutase (MnSOD) in pulmonary endothelial cells confers resistance to hyperoxia. *J Cell Physiol* 161: 237-242.
- Liu H, Nishitoh H, Ichijo H & Kyriakis JM (2000) Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. *Mol Cell Biol* 20: 2198-2208.
- Lohse DL, Denu JM, Santoro N & Dixon JE (1997) Roles of aspartic acid-181 and serine-222 in intermediate formation and hydrolysis of the mammalian protein-tyrosine-phosphatase PTP1. *Biochemistry* 36: 4568-4575.
- McLennan HR & Esposti MD (2000) The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. *J Bioenergetics Biomembranes* 32: 153-162.
- MacNee W (2001) Oxidative stress and lung inflammation in airways disease. *Eur J Pharmacol* 429: 195-207.
- Majumder PK, Mishra NC, Sun X, Bharti A, Kharbanda S, Saxena S & Kufe D (2001) Targeting of protein kinase C delta to mitochondria in the oxidative stress response. *Cell Growth Differ* 12: 465-470.
- Manevich Y, Feinstein SI & Fisher AB (2004) Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. *Proc Natl Acad Sci U S A* 101: 3780-3785.
- Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V & Fisher AB (2002) 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. *Proc Natl Acad Sci U S A* 99: 11599-11604.
- Marklund SL (1984) Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. *Biochem J* 222: 649-655.
- May JM & de Haen C (1979a) Insulin-stimulated intracellular hydrogen peroxide production in rat epididymal fat cells. *J Biol Chem* 254: 2214-2220.

- May JM & de Haen C (1979b) The insulin-like effect of hydrogen peroxide on pathways of lipid synthesis in rat adipocytes. *J Biol Chem* 254: 9017-9021.
- Meier B, Cross AR, Hancock JT, Kaup FJ & Jones OT (1991) Identification of a superoxide-generating NADPH oxidase system in human fibroblasts. *Biochem J* 275: 241-245.
- Moore RB, Plishker GA & Shriver SK (1990) Purification and measurement of calpromotin, the cytoplasmic protein which activates calcium-dependent potassium transport. *Biochem Biophys Res Commun* 166: 146-153.
- Moore RB & Shriver SK (1997) Protein 7.2b of human erythrocyte membranes binds to calpromotin. *Biochem Biophys Res Commun* 232: 294-297.
- Morrison J, Knoll K, Hessner MJ & Liang M (2004) Effect of high glucose on gene expression in mesangial cells: upregulation of the thiol pathway is an adaptational response. *Physiol Genomics* 17: 271-282.
- Mossman BT & Gee JB (1989) Asbestos-related diseases. *N Engl J Med* 320: 1721-1730.
- Mu ZM, Yin XY & Prochownik EV (2002) Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. *J Biol Chem* 277: 43175-43184.
- Mulcahy RT & Gipp JJ (1995) Identification of a putative antioxidant response element in the 5'-flanking region of the human gamma-glutamylcysteine synthetase heavy subunit gene. *Biochem Biophys Res Commun* 209: 227-233.
- Nagase T, Miyajima N, Tanaka A, Sazuka T, Seki N, Sato S, Tabata S, Ishikawa K, Kawarabayasi Y, Kotani H & et al. (1995) Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. *DNA Res* 2: 37-43.
- Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH & Van Etten RA (2003) Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. *Nature* 424: 561-565.
- Nicolls MR, D'Antonio JM, Hutton JC, Gill RG, Czwoznog JL & Duncan MW (2003) Proteomics as a tool for discovery: proteins implicated in Alzheimer's disease are highly expressed in normal pancreatic islets. *J Proteome Res* 2: 199-205.
- Nisimoto Y, Tamura M & Lambeth JD (1988) A menadione-stimulated pyridine nucleotide oxidase from resting bovine neutrophil membranes. Purification, properties, and immunochemical cross-reactivity with the human neutrophil NADPH oxidase. *J Biol Chem* 263: 11657-11663.
- Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA & Chae HZ (2001) Overexpression of peroxiredoxin in human breast cancer. *Anticancer Res* 21: 2085-2090.
- Oblong JE, Berggren M, Gasdaska PY & Powis G (1994) Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin. *J Biol Chem* 269: 11714-11720.
- Ohba M, Shibamura M, Kuroki T & Nose K (1994) Production of hydrogen peroxide by transforming growth factor-beta 1 and its involvement in induction of egr-1 in mouse osteoblastic cells. *J Cell Biol* 126: 1079-1088.
- Oikawa I & Novikoff PM (1995) Catalase-negative peroxisomes: transient appearance in rat hepatocytes during liver regeneration after partial hepatectomy. *Am J Pathol* 146: 673-687.
- Okado-Matsumoto A, Matsumoto A, Fujii J & Taniguchi N (2000) Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. *J Biochem (Tokyo)* 127: 493-501.

- Oury TD, Day BJ & Crapo JD (1996) Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. *Lab Invest* 75: 617-636.
- Pahl P, Berger R, Hart I, Chae HZ, Rhee SG & Patterson D (1995) Localization of TDPX1, a human homologue of the yeast thioredoxin-dependent peroxide reductase gene (TPX), to chromosome 13q12. *Genomics* 26: 602-606.
- Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D & Barnes PJ (2000) Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 162: 369-373.
- Park SG, Cha MK, Jeong W & Kim IH (2000a) Distinct physiological functions of thiol peroxidase isoenzymes in *Saccharomyces cerevisiae*. *J Biol Chem* 275: 5723-5732.
- Park SH, Chung YM, Lee YS, Kim HJ, Kim JS, Chae HZ & Yoo YD (2000b) Antisense of human peroxiredoxin II enhances radiation-induced cell death. *Clin Cancer Res* 6: 4915-4920.
- Pedrajas JR, Miranda-Vizuete A, Javanmardy N, Gustafsson JA & Spyrou G (2000) Mitochondria of *Saccharomyces cerevisiae* contain one-conserved cysteine type peroxiredoxin with thioredoxin peroxidase activity. *J Biol Chem* 275: 16296-16301.
- Phelan SA, Beier DR, Higgins DC & Paigen B (2002) Confirmation and high resolution mapping of an atherosclerosis susceptibility gene in mice on Chromosome 1. *Mamm Genome* 13: 548-553.
- Phelan SA, Johnson KA, Beier DR & Paigen B (1998) Characterization of the murine gene encoding Aop2 (antioxidant protein 2) and identification of two highly related genes. *Genomics* 54: 132-139.
- Phelan SA, Wang X, Wallbrandt P, Forsman-Semb K & Paigen B (2003) Overexpression of Prdx6 reduces H<sub>2</sub>O<sub>2</sub> but does not prevent diet-induced atherosclerosis in the aortic root. *Free Radic Biol Med* 35: 1110-1120.
- Poole LB, Karplus PA & Claiborne A (2004) Protein sulfenic acids in redox signaling. *Ann Rev Pharmacol Toxicol* 44: 325-47.
- Prosperi MT, Apiou F, Dutrillaux B & Goubin G (1994) Organization and chromosomal assignment of two human PAG gene loci: PAGA encoding a functional gene and PAGB a processed pseudogene. *Genomics* 19: 236-241.
- Prosperi MT, Ferbus D, Karczinski I & Goubin G (1993) A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. *J Biol Chem* 268: 11050-11056.
- Prosperi MT, Ferbus D, Rouillard D & Goubin G (1998) The pag gene product, a physiological inhibitor of c-abl tyrosine kinase, is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress. *FEBS Lett* 423: 39-44.
- Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS & Powis G (2003) Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. *J Lab Clin Med* 142: 46-51.
- Rahman Q, Viswanathan PN & Zaidi SH (1977) Some new perspectives on the biological effects of asbestos. *Environ Res* 14: 487-498.
- Ren Y & Smith A (1995) Mechanism of metallothionein gene regulation by heme-hemopexin. Roles of protein kinase C, reactive oxygen species, and cis-acting elements. *J Biol Chem* 270: 23988-23995.
- Rhee SG (1999) Redox signaling: hydrogen peroxide as intracellular messenger. *Exp Mol Med* 31: 53-59.

- Rigaudiere N, Ghyselinck NB, Faure J & Dufaure JP (1992) Regulation of the epididymal glutathione peroxidase-like protein in the mouse: dependence upon androgens and testicular factors. *Mol Cell Endocrinol* 89: 67-77.
- Rouquette M, Page S, Bryant R, Benboubetra M, Stevens CR, Blake DR, Whish WD, Harrison R & Tosh D (1998) Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. *FEBS Lett* 426: 397-401.
- Saetta M, Turato G, Maestrelli P, Mapp CE & Fabbri LM (2001) Cellular and structural bases of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 163: 1304-1309.
- Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K & Ichijo H (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. *EMBO J* 17: 2596-2606.
- Sakamoto A, Tsukamoto S, Yamamoto H, Ueda-Hashimoto M, Takahashi M, Suzuki H & Morikawa H (2003) Functional complementation in yeast reveals a protective role of chloroplast 2-Cys peroxiredoxin against reactive nitrogen species. *Plant J* 33: 841-851.
- Sanchez-Font MF, Sebastia J, Sanfeliu C, Cristofol R, Marfany G & Gonzalez-Duarte R (2003) Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains. *Cell Mol Life Sci* 60: 1513-1523.
- Sasagawa I, Matsuki S, Suzuki Y, Iuchi Y, Tohya K, Kimura M, Nakada T & Fujii J (2001) Possible involvement of the membrane-bound form of peroxiredoxin 4 in acrosome formation during spermiogenesis of rats. *Eur J Biochem* 268: 3053-3061.
- Schroder E, Littlechild JA, Lebedev AA, Errington N, Vagin AA & Isupov MN (2000) Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 Å resolution. *Structure Fold Des* 8: 605-615.
- Schulz H (1991) Beta oxidation of fatty acids. *Biochim Biophys Acta* 1081: 109-120.
- Schwaab V, Faure J, Dufaure JP & Drevet JR (1998) GPx3: the plasma-type glutathione peroxidase is expressed under androgenic control in the mouse epididymis and vas deferens. *Mol Reprod Dev* 51: 362-372.
- Seo EY, Piao YJ, Kim JS, Suhr KB, Park JK & Lee JH (2002) Identification of calcium-induced genes in HaCaT keratinocytes by polymerase chain reaction-based subtractive hybridization. *Arch Dermatol Res* 294: 411-418.
- Seo MS, Kang SW, Kim K, Baines IC, Lee TH & Rhee SG (2000) Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. *J Biol Chem* 275: 20346-20354.
- Seo MS, Kim JK, Lim Y, Kang SW, Cho YJ, Lee WK, Kim HJ, Cho KK, Lee KH & Rhee SG (1999) Rapid degradation of PrxI and PrxII induced by silica in Rat2 cells. *Biochem Biophys Res Commun* 265: 541-544.
- Shau H, Butterfield LH, Chiu R & Kim A (1994) Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. *Immunogenetics* 40: 129-134.
- Shih SF, Wu YH, Hung CH, Yang HY & Lin JY (2001) Abrin triggers cell death by inactivating a thiol-specific antioxidant protein. *J Biol Chem* 276: 21870-21877.
- Sparling NE & Phelan SA (2003) Identification of multiple transcripts for antioxidant protein 2 (Aop2): differential regulation by oxidative stress and growth factors. *Redox Rep* 8: 87-94.
- Spector A, Yan GZ, Huang RR, McDermott MJ, Gascoyne PR & Pigiet V (1988) The effect of H<sub>2</sub>O<sub>2</sub> upon thioredoxin-enriched lens epithelial cells. *J Biol Chem* 263: 4984-4990.
- St Clair DK, Jordan JA, Wan XS & Gairola CG (1994) Protective role of manganese superoxide dismutase against cigarette smoke-induced cytotoxicity. *J Toxicol Environ Health* 43: 239-249.

- St Clair DK, Oberley TD & Ho YS (1991) Overproduction of human Mn-superoxide dismutase modulates paraquat-mediated toxicity in mammalian cells. *FEBS Lett* 293: 199-203.
- Sundaresan M, Yu ZX, Ferrans VJ, Irani K & Finkel T (1995) Requirement for generation of H<sub>2</sub>O<sub>2</sub> for platelet-derived growth factor signal transduction. *Science* 270: 296-299.
- Sundaresan M, Yu ZX, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ & Finkel T (1996) Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. *Biochem J* 318 ( Pt 2): 379-382.
- Talior I, Tennenbaum T, Kuroki T & Eldar-Finkelman H (2005) PKC- $\delta$ -dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. *Am J Physiol Endocrinol Metab* 288: E405-E411.
- Thannickal VJ & Fanburg BL (2000) Reactive oxygen species in cell signaling. *Am J Physiol Lung Cell Mol Physiol* 279: L1005-L1028.
- Toledano MB & Leonard WJ (1991) Modulation of transcription factor NF- $\kappa$ B binding activity by oxidation-reduction in vitro. *Proc Natl Acad Sci U S A* 88: 4328-4332.
- Tsujii K, Copeland NG, Jenkins NA & Obinata M (1995) Mammalian antioxidant protein complements alkylhydroperoxide reductase (ahpC) mutation in *Escherichia coli*. *Biochem J* 307 ( Pt 2): 377-381.
- Verdoux L, Vignols F, Jacquot JP, Chartier Y & Meyer Y (1999) In vivo characterization of a thioredoxin h target protein defines a new peroxiredoxin family. *J Biol Chem* 274: 19714-19722.
- Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J & Tursz T (1990) Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. *Proc Natl Acad Sci U S A* 87: 8282-8286.
- Wang X, Phelan SA, Forsman-Semb K, Taylor EF, Petros C, Brown A, Lerner CP & Paigen B (2003) Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. *J Biol Chem* 278: 25179-25190.
- Wang Y, Manevich Y, Feinstein SI & Fisher AB (2004) Adenovirus-mediated transfer of the 1-cys peroxiredoxin gene to mouse lung protects against hyperoxic injury. *Am J Physiol Lung Cell Mol Physiol* 286: L1188-L1193.
- Wattiez R, Hermans C, Bernard A, Lesur O & Falmagne P (1999) Human bronchoalveolar lavage fluid: two-dimensional gel electrophoresis, amino acid microsequencing and identification of major proteins. *Electrophoresis* 20: 1634-1645.
- Wen ST & Van Etten RA (1997) The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. *Genes Dev* 11: 2456-2467.
- Winterbourn CC, Vissers MC & Kettle AJ (2000) Myeloperoxidase. *Curr Opin Hematol* 7: 53-58.
- Wong CM, Chun AC, Kok KH, Zhou Y, Fung PC, Kung HF, Jeang KT & Jin DY (2000) Characterization of human and mouse peroxiredoxin IV: evidence for inhibition by Prx-IV of epidermal growth factor- and p53-induced reactive oxygen species. *Antioxid Redox Signal* 2: 507-518.
- Wong CM, Zhou Y, Ng RW, Kung Hf HF & Jin DY (2002) Cooperation of yeast peroxiredoxins Tsa1p and Tsa2p in the cellular defense against oxidative and nitrosative stress. *J Biol Chem* 277: 5385-5394.



- Wonsey DR, Zeller KI & Dang CV (2002) The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. *Proc Natl Acad Sci U S A* 99: 6649-6654.
- Woo HA, Jeong W, Chang TS, Park KJ, Park SJ, Yang JS & Rhee SG (2004) Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-Cys peroxiredoxins. *J Biol Chem* 280: 3125-3128.
- Woo HA, Chae HZ, Hwang SC, Yang K-S, Kang SW, Kin K & Rhee SG (2003) Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. *Science* 300: 653-656.
- Wood ZA, Poole LB, Hantgan RR & Karplus PA (2002) Dimers to doughnuts: redox-sensitive oligomerization of 2-cysteine peroxiredoxins. *Biochemistry* 41: 5493-5504.
- Yamashita H, Avraham S, Jiang S, London R, Van Veldhoven PP, Subramani S, Rogers RA & Avraham H (1999) Characterization of human and murine PMP20 peroxisomal proteins that exhibit antioxidant activity in vitro. *J Biol Chem* 274: 29897-29904.
- Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, Omura K, Suzuki H & Yoshida H (1999) Peroxiredoxin I expression in human thyroid tumors. *Cancer Lett* 145: 127-132.
- Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, Omura K, Harada H, Suzuki H & Yoshida H (2000) Peroxiredoxin I expression in oral cancer: a potential new tumor marker. *Cancer Lett* 156: 27-35.
- Yoo YD, Chung YM, Park JK, Ahn CM, Kim SK & Kim HJ (2002) Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death. *Exp Mol Med* 34: 273-277.
- Zangar RC, Davydov DR & Verma S (2004) Mechanisms that regulate production of reactive oxygen species by cytochrome P450. *Toxicol Appl Pharmacol* 199: 316-331.
- Zhang P, Liu B, Kang SW, Seo MS, Rhee SG & Obeid LM (1997) Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. *J Biol Chem* 272: 30615-30618.
- Zhou Y, Kok KH, Chun AC, Wong CM, Wu HW, Lin MC, Fung PC, Kung H & Jin DY (2000) Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53- induced apoptosis. *Biochem Biophys Res Commun* 268: 921-927.
- Zulueta JJ, Yu FS, Hertig IA, Thannickal VJ & Hassoun PM (1995) Release of hydrogen peroxide in response to hypoxia-reoxygenation: role of an NAD(P)H oxidase-like enzyme in endothelial cell plasma membrane. *Am J Respir Cell Mol Biol* 12: 41-49.